

1 **Biosynthesis of 14-membered cyclopeptide alkaloids via non-heme-iron- and 2-oxoglutarate-**
2 **dependent oxidative decarboxylation**

3 Jordan Hungerford^{1,x}, Lisa S. Mydy^{1,x}, Xiaofeng Wang^{1,x}, Lorena Mendoza-Perez¹, Derrick A. Ousley¹,
4 Khadija Shafiq¹, Kali M. McDonough¹, Wenjie Li¹, Gabrielle May¹, Desnor N. Chigumba¹, Shengrui Yao²,
5 Roland D. Kersten¹

6
7 1 - Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, 48109, USA

8 2 - Department of Plant and Environmental Sciences, Sustainable Agriculture Science Center at Alcalde,
9 New Mexico State University, Alcalde, NM, 87511, USA

10 x - contributed equally to this manuscript

11 * – corresponding author: rkersten@umich.edu

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Abstract:**

34 Cyclopeptide alkaloids are an expanding class of plant peptide natural products defined by a macrocyclic
35 ether-crosslink via a tyrosine-derived phenol. Classical cyclopeptide alkaloids are characterized by strained
36 13- to 15-membered cyclophanes and terminal modifications such as *N*-methylation and C-terminal
37 styrylamine moieties. While synthetic access to many classical cyclopeptide alkaloids has been established,
38 no biosynthetic route has been reported. Here, we elucidate the biosynthetic pathway of a 14-membered
39 cyclopeptide alkaloid, lotusine A, from Chinese date tree (*Ziziphus jujuba*) which features peptide cyclization
40 on a ribosomal precursor peptide by a split burpitide cyclase, non-heme-iron and 2-oxoglutarate-dependent
41 oxidative decarboxylation affording the C-terminal hydroxystyrylamine, and SAM-dependent N-terminal α -
42 *N,N*-dimethylation. We apply discovered *Z. jujuba* enzymes in combination with a clubmoss cyclopeptide
43 alkaloid cyclase for biosynthesis and diversification of analgesic adouetine X and anxiolytic sanjoinine A by
44 combining *in planta* and *in vitro* reactions. Our work expands the biocatalytic repertoire of non-heme-iron-
45 and 2-oxoglutarate-dependent enzymology to oxidative peptide decarboxylation and primes scaled
46 metabolic engineering and chemoenzymatic synthesis of 14-membered cyclopeptide alkaloids with terminal
47 posttranslational modifications.

48 Introduction

49 Cyclopeptide alkaloids (CPAs) are a diverse class of plant peptides, which were structurally first
50 characterized in the 1960s as small cyclic peptides featuring 13- to 15-membered macrocycles from
51 buckthorn (Rhamnaceae) plants¹. CPAs have medicinal activities such as analgesic adouetine X^{2,3},
52 anxiolytic sanjoinine A⁴, and antiviral jubanines⁵ and have therefore been leads for medicinal chemistry
53 (**Figure 1A, Figure S1**). Most CPAs are structurally characterized by an ether-crosslink between a C-
54 terminal hydroxystyrylamine, tyrosine, or octopamine to an unactivated β -carbon of another amino acid
55 such as leucine (33% of known CPAs, **Data S1**), proline (40% of known CPAs), or phenylalanine (21% of
56 known CPAs)^{6,7}. In addition, classical CPAs feature terminal modifications such as α -*N,N*-dimethylation
57 (54% of known CPAs) and a C-terminal hydroxystyrylamine (87% of known CPAs, **Data S1**)^{6,7}. Despite
58 their promising bioactivities and drug-like properties, exploration of CPAs for drug discovery has been
59 limited by low isolation yields from source plants and synthetic challenges of the strained macrocycles, the
60 C-terminal enamide and peptide diversification^{8,9}.

61 Recently, plant cyclopeptides with tyrosine-derived C-O-crosslinks such as 14-membered selanine
62 B from *Selaginella kraussiana* were biosynthetically defined as ribosomally-synthesized and
63 posttranslationally modified peptides (RiPP)¹⁰ called burptides^{7,11,12}, which are derived from copper-
64 dependent peptide cyclases with BURP domains^{11–15}. Selanine B is macrocyclized by ether-crosslinking of
65 a C-terminal tyrosine-phenol-hydroxy to a leucine- β -carbon in an autocatalytic copper-dependent reaction
66 by burptide cyclase SkrBURP that is fused to its core peptide substrates and also generates bicyclic
67 cyclopeptide alkaloids with an additional 17-membered C-terminal macrocycle such as selanine A via a
68 second C-terminal tyrosine-crosslink (**Figure S1**)¹¹. Another example of a CPA-burptide with a C-O-
69 macrocyclic bond found is arabipeptin A, which is a 17-membered cyclopeptide. Arabipeptin A core peptide
70 is cyclized by ArbB, a burptide cyclase which is split from its core peptide substrates in a separate precursor
71 peptide^{12,15} co-localized on the genome with its burptide cyclase. Both arabipeptin A and selanine B lack
72 the enamine moiety of classical CPAs as they have a C-terminal carboxy group. Based on the formation of
73 CPA-type ether crosslinks formed by burptide cyclases such as SkrBURP, it has been proposed to re-
74 classify CPAs on the basis of biosynthesis as burptides with tyrosine-derived ether crosslinks⁷.

75 Burptide cyclases contain a dicopper center defined by a 4xCysHis-motif within the BURP-domain
76 fold¹⁴. Burptide cyclases such as legumenin cyclase AhyBURP catalyze crosslinking of an aromatic residue
77 such as tryptophan or tyrosine with a C(*sp*³) carbon in another amino acid of a core peptide motif by a
78 radical, dioxygen-dependent reaction^{14,16}. Decarboxylated peptide C-termini as observed in classical CPAs
79 occur in several bacterial RiPPs such as lanthipeptides, linaridins, and bottromycins (**Figure S1**)^{17–22}. In
80 lanthipeptides and linaridins, which feature a C-terminal aminovinyl-cysteine posttranslational modification,
81 a C-terminal cysteine is oxidatively decarboxylated by a flavoenzyme (**Figure 1B**)^{17–22}. Bottromycins
82 contain a C-terminal thiazole formed from a thiazoline through oxidative decarboxylation by a CYP450
83 enzyme (**Figure 1C**)²³. Other C-terminal decarboxylation reactions in RiPP biosynthesis were reported in
84 mycofactocin biosynthesis via a radical *S*-adenosyl-L-methionine (SAM) enzyme mechanism (**Figure**
85 **1D**)^{24,25} and for the formation of a *Burkholderia* RiPP with a C-terminal β -amino- α -keto acid generated by a
86 multinuclear non-heme-iron oxidative enzyme (**Figure 1E**)²⁶. Similarly, multiple RiPP classes such as
87 lanthipeptides^{27–30}, linaridins²¹, phomopsins^{31,32}, linear azol(in)e-containing peptides³³ have N-terminal α -*N*-
88 methylations that are often generated by SAM-dependent methyltransferases (**Figure S1**)³⁴. Burptides
89 selanine B and arabipeptin A also contain α -*N,N*-dimethylation but the biosynthetic basis of this modification
90 is unknown.

91 Here, we establish the biosynthetic pathway to 14-membered CPAs with N-terminal α -*N*-
92 methylation and C-terminal oxidative decarboxylation from *Ziziphus jujuba* and utilize the discovered
93 enzymes including a non-heme-iron and 2-oxoglutarate-dependent decarboxylase for the biosynthesis of
94 proline- and leucine-macrocyclic CPAs such as lotusine A and analgesic adouetine X, respectively.

95
96

97 Results

98 Characterization of 14-membered CPA-burpitide cyclase ZjuBURP

99 To elucidate a classical CPA biosynthetic pathway, we targeted Chinese date tree (*Ziziphus jujuba*,
100 Rhamnaceae), a common source plant of medicinal CPA chemistry including adouetine X, sanjoinine A
101 and jubanines. Chekan and colleagues identified through bioinformatics candidate split precursor genes of
102 13- and 14-membered CPAs in the *Z. jujuba* genome (**Figure 2A**), which co-localize with BURP-domain-
103 encoding genes of the BNM2 subfamily^{12,35}. These proposed burpitide precursor genes constitute an entry
104 point to biosynthetic pathway elucidation of classical CPAs featuring both ether-crosslinks, alkylated N-
105 termini and decarboxylated C-termini, which are highly diversified in *Ziziphus* plants^{6,7}. To characterize a
106 burpitide cyclase, we chose a BURP-domain-containing gene co-localized with a candidate precursor gene
107 on chromosome 9 of *Z. jujuba* cultivar Dongzao³⁶ which had eleven predicted core peptides of FPIY and
108 three predicted core peptides of FLIY (**Figure 2A**). FPIY matched previously identified cyclopeptide
109 alkaloids from *Ziziphus* sp. such as 14-membered lotusine A and 13-membered daechuine S26 (**Figure**
110 **S1**)^{37,38}.

111 We tested if the BURP-domain-containing gene encodes a split burpitide cyclase such as ArbB that
112 is involved in macrocyclization of core peptides such as FPIY motifs encoded in the co-localized precursor
113 gene. A truncated version of the target precursor gene with five FPIY core peptide repeats, named ZjuPrec-
114 5xFPIY, was synthesized, cloned and expressed with the pEAQ-HT plasmid in transgenic *Nicotiana*
115 *benthamiana* via agroinfiltration for seven days³⁹. Methanol extracts of the transgenic *N. benthamiana*
116 leaves showed no analytes corresponding to a monocyclic FPIY peptide (**Figure 2B**). Co-expression of
117 pEAQ-HT-ZjuPrec-5xFPIY and the candidate burpitide cyclase gene *ZjuBURP* led to the detection of an
118 analyte with an *m/z* value of 537.271 corresponding to a monocyclic FPIY peptide with unmodified peptide
119 termini ([M+H]⁺, **Figure 2B**). To determine the structure of analyte cyFPIY (**1**), we applied a scaled
120 expression of the cyclase-precursor peptide pair in *N. benthamiana*. To optimize yields, we tested if a fused
121 version of the split burpitide cyclase and the truncated precursor peptide would improve cyFPIY yields in
122 transgenic *N. benthamiana*. Expression of ZjuPrec-5xFPIY-ZjuBURP-fusion yielded the same cyFPIY
123 product from the split system while increasing yields by 2.9-fold from agroinfiltration based on cyFPIY EIC
124 area-under-the-curve values from infiltrated tobacco leaf extracts (**Figure 2B, Figure S2**). Scaled
125 expression of the fusion gene enabled reproducible production of 5 mg pure cyFPIY (**1**) per 1 kg of tobacco
126 wet weight. 1D and 2D NMR analysis of **1** revealed a 14-membered FPIY peptide in which the macrocyclic
127 C-O-crosslink is between the C-terminal tyrosine-phenol-hydroxy group and the β -carbon of the proline
128 (**Figure 2C, Figures S3-S10, Table S1**). Marfey's analysis showed L-Phe, L-Pro, L-Ile, and L-Tyr (**Figure**
129 **S11**). In the ROESY spectrum, a correlation is observed between Pro2-H α and Trp4-H5, as well as between
130 Pro2-H β and Trp4-H3. Together with the *J*-value of 7 Hz for the C α -C β bond in Pro2, this indicates an L-
131 erythro stereochemistry, corresponding to an S-configuration at the Pro2 C β position (**Figure S6, Table**
132 **S1**)⁴⁰.

133 *In vitro* reconstitution of ZjuBURP was challenged by low protein yields. The production of a cyclic
134 14-membered CPA from transgenic *N. benthamiana* expressing ZjuBURP in the presence of a split
135 predicted CPA precursor peptide such as ZjuPrec-FPIY suggests that ZjuBURP is a burpitide cyclase
136 installing the ether-crosslink on the core peptide of the precursor peptide, which is further processed
137 proteolytically to cyFPIY during CPA biosynthesis in *Z. jujuba*. *In vitro* precedence for split 14-membered
138 CPA cyclization was recently provided by ArbB and a ZjuBURP-homologous split burpitide cyclase,
139 CamBURP1 from *Ceanothus americanus*, which were reconstituted as a copper-dependent peptide
140 cyclases¹⁵.

141
142 **Discovery of a non-heme-iron and 2-oxoglutarate-dependent CPA-decarboxylase from jujube**
143 Next, we explored jujube for biosynthetic genes involved in the terminal modifications of CPAs after we
144 established a CPA-burpitide cyclase. A *Ziziphus jujuba* var. Dongzao cultivar was obtained and analyzed
145 for the presence of CPAs in its mature leaf and stem tissues. While no CPAs such as lotusine A matching

146 an FPIY core peptide could be detected in jujube samples, a candidate CPA analyte with an m/z value of
147 696.3756 was detected in high abundance in mature stem tissue via CPA-targeted molecular networking
148 (**Figure S12**). This CPA was isolated and structurally elucidated by 1D and 2D NMR, Marfey's analysis
149 and PGME derivatization (**Figure S13-21, Table S2**)⁴¹ to be a 13-membered CPA with a FIPFY core
150 peptide, α -*N,N*-dimethylation on its N-terminus, and a meta-crosslinked hydroxystyrylamine moiety with an
151 ortho-methoxy group (**Figure S22**). This peptide is a new CPA named jubanine K, which showed that the
152 target *Ziziphus jujuba* plants have the metabolic capacity for oxidative decarboxylation and N-methylation
153 of CPAs.

154 To identify the enzymes catalyzing the N-terminal modifications of jujube CPAs, we used a multi-
155 omic approach to find gene candidates upregulated in tissues with increased CPA content. Young stem
156 and leaf tissues of the same cultivar used for jubanine K isolation showed low levels of jubanine K in its
157 stem tissue and no jubanine K mass signals in the young leaves. However, a putative biosynthetic
158 intermediate for jubanine K without the methoxy group was detected in high ion abundance in young stems
159 compared to young leaves (**Figure S22**). To identify candidate genes for terminal CPA modifications, young
160 stem and young leaf mRNA were sequenced by RNA-seq. Using ZjuPrec-FPIY as a query, a candidate
161 jubanine K precursor peptide was identified by BLAST search⁴² in the assembled transcriptome which
162 features a core peptide of FIPFY matching jubanine K structure and was coexpressed with ZjuBURP (**Table**
163 **S3**). Co-expression of this precursor peptide with ZjuBURP yielded a monocyclic FIPFY analyte based on
164 MS/MS analysis indicating that ZjuBURP is part of the jubanine K biosynthetic pathway (**Figure S23**). We
165 hypothesized that either *N*-methylation or decarboxylation could occur after the cyclization and a proteolytic
166 processing step to yield the cyclic core peptide. Both routes were supported based on the detection of low
167 intensity analytes corresponding to *N,N*-dimethylated cyclic FIPFY and decarboxylated cyclic FIPFY in
168 young *Z. jujuba* stem extracts (**Figure S22**). Using ZjuBURP as a bait gene, we searched for oxidase genes,
169 which were upregulated in young stems compared to young leaves. Several CYP450 and non-heme-iron
170 dioxygenase genes with similar expression patterns as ZjuBURP (**Table S3**) were synthesized, cloned into
171 pEAQ-HT, and co-expressed with ZjuPrec-5xFPIY-ZjuBURP-fusion in *N. benthamiana*. One dioxygenase
172 gene, named ZjuDC, yielded an analyte in *N. benthamiana* co-expression experiments, which had a mass
173 loss corresponding to oxidative decarboxylation, i.e. a mass loss of two hydrogens and CO₂, compared to
174 cyFPIY (**Figure 3A**). Bioinformatic analysis predicted *ZjuDC* to encode a member of the non-heme-iron and
175 2-oxoglutarate (2OG)-dependent dioxygenase family, as the sequence and AlphaFold3⁴³ model of ZjuDC
176 revealed the characteristic iron-coordinating His-X-(Asp/Glu)-X₄₈₋₁₅₃-His motif in comparison to
177 experimentally determined structures of homologous plant dioxygenases (**Figure S24**)⁴⁴⁻⁴⁷.

178 To test ZjuDC decarboxylation of cyFPIY, ZjuDC was expressed heterologously in *E. coli*
179 BL21(DE3) and purified via immobilized metal affinity chromatography and size exclusion chromatography
180 (**Figure S25**). *In vitro* incubation of ZjuDC with cyFPIY in the presence of 2-oxoglutarate (2-OG), O₂ and
181 Fe(II) yielded the decarboxylated analyte cyFPIY-dc (**2**) observed *in planta* (**Figure 3B**). Further *in vitro*
182 enzyme assays showed that the ZjuDC reaction requires 2OG, O₂ and Fe(II) for the conversion of cyFPIY
183 into **2** (**Figure 3C**) while generating succinate (**Figure S26**). We tried to generate analyte **2** at scale in *N.*
184 *benthamiana*, however its purification was challenging from transgenic leaves to reach milligram quantities.
185 Therefore, we purified 5.5 mg of cyFPIY from transgenic *N. benthamiana* via ZjuPrec-5xFPIY-ZjuBURP-
186 fusion expression and converted it in a scaled *in vitro* ZjuDC reaction to **2** for further purification and
187 structure elucidation. MS and MS/MS analysis of **2** showed the loss of 46.01 Da corresponding to C-terminal
188 oxidative decarboxylation compared to **1** and 1D and 2D NMR analysis of purified **2** confirmed the presence
189 of a *p*-hydroxystyrylamine at the C-terminus of **2** (**Figures 3D & 3E, Figure S27-34, Table S4**). The
190 stereochemical analysis of **2** also showed the same L-configuration of Phe1, Pro2, and Ile3 compared to
191 cyFPIY based on Marfey's analysis, while the C-terminal alkene is in a *cis*-configuration given its *J*-value
192 of 7 Hz (**Figure 3E, Figures S35, Table S4**). Since this is the first example of a 2OG-dependent non-heme
193 iron enzyme catalyzing styrylamine formation, we used steady state kinetics as an indicator for affinity and
194 turnover values for the cyclic peptide substrate. Kinetic analysis of ZjuDC with purified cyFPIY had a K_m of

195 3.51±0.98 μM , $k_{\text{cat}} = 0.67\pm0.10 \text{ min}^{-1}$, and $k_{\text{cat}}/K_{\text{m}} = 0.19 \mu\text{M}^{-1} \text{ min}^{-1}$ (**Figure 3F**). In summary, RNA-seq
196 analysis enabled us to discover a non-heme-iron and 2OG-dependent decarboxylase catalyzing the
197 characteristic C-terminal modification of classical CPAs and brought us one step closer to a complete
198 biosynthesis of a classical CPA.

199

200 **Characterization of a CPA-burpitide *N*-methyltransferase from jujube**

201 Having identified the biosynthetic enzyme responsible for styrylamine formation, we applied differential
202 gene expression analysis of young jujube shoot tissues to identify an *N*-methyltransferase to complete the
203 biosynthetic pathway for select 14-membered CPAs. ZjuDC was used as a bait gene for the identification
204 of candidate methyltransferases with high correlation coefficients (**Table S3**). In addition to annotated *N*-
205 methyltransferases, *O*-methyltransferases were used as candidate genes as they could have evolved to
206 methylate amines or possess generalist activity allowing them to methylate both amines and alcohols⁴⁸.
207 Nine candidate genes encoding five *N*-methyltransferases and four *O*-methyltransferases were co-
208 expressed with ZjuPrec-5xFPIY-ZjuBURP-fusion and ZjuDC as pEAQ-HT constructs in *Nicotiana*
209 *benthamiana* via agroinfiltration. Infiltrated tobacco leaves were collected seven days later, extracted with
210 80% methanol and analyzed by LC-MS. The leaf extracts revealed an analyte with a mass shift
211 corresponding to the *N,N*-dimethylated product of cyFPIY-dc in the presence of candidate
212 methyltransferase ZjuNMT (**Figure 4A**). Bioinformatic analysis predicted ZjuNMT being a SAM-dependent
213 *O*-methyltransferase (**Table S3**). ZjuNMT was recombinantly expressed and purified from *E. coli*
214 BL21(DE3) to validate its function (**Figure S25**). Incubation of ZjuNMT with cyFPIY-dc and SAM as a methyl
215 donor resulted in formation of a dimethylated analyte by LC-MS/MS analysis (**Figure 4B**). Interestingly,
216 ZjuNMT also generated mono- and trimethylated CPA products *in planta* and *in vitro* (**Figure S36**). A time
217 course for the ZjuNMT reaction with cyFPIY substrate revealed that the dimethylation product is highest in
218 10 min reaction time in the presence of 1 mM SAM as this condition showed lowest amounts of other
219 methylation side products (**Figure S36**). To structurally confirm a ZjuNMT product, cyFPIY-dc (**2**) was
220 reacted *in vitro* at milligram-scale by ZjuNMT reaction to its *N,N*-dimethylated analog. The resulting CPA
221 was purified and structurally characterized (**Figure 4C, Figure S37-44, Table S5**). NMR and Marfey's
222 analysis and PGME derivatization of the reaction product characterized the 3D structure of lotusine A with
223 L-configuration at the amino acid α -carbons S-configuration at the crosslink- β -carbon (**Figure S45**).
224 ZjuNMT was able to methylate both cyFPIY to *N,N*-Me₂-cyFPIY (**4**) and cyFPIY-dc (**2**) to lotusine A,
225 respectively, indicating its substrate promiscuity within *Ziziphus* CPA biosynthesis (**Figure 4B, 4D, & Figure**
226 **S36**). A cofactor screen of ZjuNMT revealed its SAM-dependent product formation (**Figure 4D**). Therefore,
227 ZjuNMT discovery enabled the full reconstitution of 14-membered classical CPA biosynthesis.

228

229 **Biosynthesis of adouetine X and sanjoinine A with ZjuDC and ZjuNMT**

230 With two enzymes for terminal CPA modifications discovered, we tested if they can be applied for
231 biosynthesis of medicinal CPAs. Two target CPAs with interesting medicinal properties are adouetine X
232 and sanjoinine A (**Figure 1A**): adouetine X shows analgesic properties in a mouse model and sanjoinine A
233 has anxiolytic activity by targeting GABA signaling^{3,4}. To enable drug development of these CPAs, a
234 biosynthetic route with potential for diversification is desired. Adouetine X and sanjoinine A are Leu-CPAs,
235 i.e. their ether-crosslink connects the C-terminal phenol with a leucine- β -carbon. To enable biosynthesis of
236 Leu-CPAs, we applied SkrBURP which is a fused burpitide cyclase from African clubmoss (*Selaginella*
237 *kraussiana*). SkrBURP produces both macrocycles for mono- and bicyclic CPAs such as selanine B and
238 selanine A, and it generates a 14-membered macrocycle in both CPA products by crosslinking a tyrosine-
239 phenol-ring to a leucine-C β via an ether bond (**Figure 1A, Figure S1**). Based on their structures, adouetine
240 X and sanjoinine A could be derived from cyLLIY (**5**) and cyFLLY (**6**) peptides by sequential C-terminal
241 decarboxylation and *N,N*-dimethylation (**Figure 5A**). To establish biosynthetic routes to adouetine X or
242 sanjoinine A, we used SkrBURP mutants with either LLIY or FLLY core peptides (**Figure 1, Figure S46**).
243 To optimize cyclic peptide yields from transient expression of SkrBURP in *N. benthamiana*, we tested

244 constructs with one or five FLLY core peptides with either a C-terminal tyrosine (FLLYxxY) or phenylalanine
245 (FLLYxxF) of the core peptide of bicyclic selanine A (core: xLxYxxY). The core peptide FLLYxxF was
246 designed to prohibit bicyclization and increase monocyclic product formation, i.e. the 14-membered ring of
247 the selanine scaffold (**Figure S46**). Among tested SkrBURP constructs, SkrBURP-5xFLLYxxF generated
248 the most cyFLLY *in planta* and both FLLYxxF constructs increased monocyclic yields compared to FLLYxxY
249 constructs by 7-9-fold (**Figure S47**). Therefore, we designed and synthesized two *SkrBURP* variants with
250 five core peptides of LLIYxxF or five core peptides of FLLYxxF for biosynthesis of cyLLIY and cyFLLY,
251 respectively (**Figure S46**). Transient expression of *SkrBURP-5xLLIYxxF* and *SkrBURP-5xFLLYxxF* in *N.*
252 *benthamiana* yielded analytes with the expected *m/z* values of cyLLIY and cyFLLY (**Figure 5B**). To confirm
253 their structures, both peptides were purified from 1-1.2 kg of transgenic *N. benthamiana*. NMR and Marfey's
254 analysis showed the predicted CPA intermediates towards sanjoinine A and adouetine X (**Figures S48-**
255 **S56 & S57-S65, Tables S6 & S7**). Co-expression of *SkrBURP-5xLLIYxxF* or *SkrBURP-5xFLLYxxF* with
256 both decarboxylase ZjuDC and *N*-methyltransferase ZjuNMT in *N. benthamiana* yielded analytes in
257 methanol extracts of leaves seven days after agroinfiltration which matched authentic standards of
258 sanjoinine A isolated from *Ziziphus cambodiana* and adouetine X isolated from *Ceanothus americanus*
259 (**Figure 5C, Figures S66-S73 & Figures S74-S83, Tables S8 & S9**). We further tested if ZjuDC and
260 ZjuNMT could be applied for *in vitro* biosynthesis of our target CPAs. Using cyLLIY or cyFLLY isolated from
261 transgenic *N. benthamiana* as a starting point, ZjuDC and ZjuNMT could convert the substrates to the
262 desired products in sequential reactions or in a one-pot-reaction (**Figure 5C**) indicating that the discovered
263 enzymes from *Z. jujuba* have potential for biocatalytic applications towards the production of other CPAs
264 than lotusine A. Finally, we tested ZjuDC and ZjuNMT for diversification of sanjoinine A and adouetine X *in*
265 *planta*. Transient expression of *SkrBURP* constructs with all proteinogenic analogs of either FLxY or LlxY
266 cores distributed in four 5xcore constructs resulted in the detection of 17 cyFLxY and 18 cyLLxY analogs
267 in methanol extracts of transgenic *N. benthamiana* leaves (**Figure 5D, Figures S84 & S85**). These cyclic
268 CPA intermediates could then be intermediates for ZjuDC and ZjuNMT via *in planta* co-expression
269 experiments. Seven sanjoinine analogs with hydrophobic residues (Ala, Ile, Leu, Val), threonine or serine
270 at position 3 and four adouetine X analogs with hydrophobic residues (Ile, Leu, Val) or threonine at position
271 3 were generated (**Figure 5D, Figures S86 & S87**). Therefore, a total of ~30% of possible analogs could
272 be generated via the *Ziziphus* CPA biosynthetic enzymes in *N. benthamiana*.

273

274 Discussion

275 Over the last decades, multiple synthetic strategies have been developed to generate strained macrocycles
276 and C-terminal enamides for the production of classical 14-membered cyclopeptide alkaloids^{8,9}. Here, we
277 present a biosynthetic route to classical cyclopeptide alkaloids with leucine and proline ether crosslinks
278 including analgesic adouetine X and anxiolytic sanjoinine A. The elucidated CPA biosynthetic pathway from
279 *Ziziphus jujuba* features ribosomal synthesis of a repetitive precursor peptide, a split burpitide cyclase for
280 14-membered core peptide macrocyclization, one or more putative proteases for core peptide proteolysis,
281 a non-heme-iron and 2OG-dependent enzyme for C-terminal oxidative decarboxylation and a SAM-
282 dependent methyltransferase for α -*N*-methylation (**Figure S88**). Compared to synthetic routes, which can
283 be up to 20 steps long such as for sanjoinine A⁴⁹, the elucidated biosynthetic pathway includes only five
284 steps and enables diversification at the non-aromatic crosslinking residue by exchange of cyclases with
285 different substrate specificity and at non-crosslinked residues by core peptide mutagenesis.

286 The first step in CPA biosynthesis is the formation of the ether crosslink by a burpitide cyclase
287 (**Figure S88**). As a member of the BNM2 BURP-domain-containing proteins, ZjuBURP is a split burpitide
288 cyclase with a separate precursor peptide. Interestingly, ZjuBURP has a precursor gene co-localized in the
289 *Z. jujuba* genome on chromosome 9 for lotusine A as predicted previously¹² but it also appears to be active
290 on precursor peptide ZjuPrec-FIPFY which is encoded on chromosome 4 without a co-localized BURP
291 domain-containing gene. This is an example of a split burpitide precursor gene not being co-localized with
292 a burpitide cyclase gene but being co-expressed (**Table S3**). Fusion of ZjuBURP with truncated ZjuPrec-

293 FPIY generated higher cyclic peptide yields in transgenic *N. benthamiana* which could be due to higher
294 catalytic efficiency because of substrate proximity to the burpitide cyclase active site, less proteolytic
295 degradation of the core peptide domain in *N. benthamiana*, or higher precursor peptide expression as a
296 fused construct given higher relative OD₆₀₀ during agroinfiltration. Challenges of split burpitide cyclases as
297 biocatalysts for the formation of CPA biosynthetic intermediates are their low protein yields for *in vitro*
298 reactions. As exemplified in our work, this issue can be addressed by three metabolic engineering strategies
299 *in planta*⁵⁰: (a) identification of other CPA-burpitide cyclases such as SkrBURP by mining plant omics
300 data^{11,51,52}, (b) by optimization of core peptide repeats on precursor peptides⁵³, and (c) reduction of shunt
301 products such as bicyclic CPAs in SkrBURP. The second step in CPA biosynthesis is proteolysis of cyclic
302 core peptides from modified precursor peptides. The identity of proteases involved in either CPA source
303 plants such as *Ziziphus jujuba* or heterologous host plant *Nicotiana benthamiana* is unknown but their
304 identification and co-expression with CPA biosynthetic genes could further boost the yields of CPAs *in*
305 *planta* and enable their production from precursor peptides *in vitro*^{54–57}.

306 The third step in CPA biosynthesis is the oxidative decarboxylation of cyclic peptide intermediates
307 by non-heme-iron and 2OG-dependent enzyme ZjuDC. This enzyme is an example of plant non-heme-iron
308 enzymes as a potential source for new biocatalysts^{58,59} as it introduces a new desaturation reaction to this
309 enzyme family which involves the loss of a C-terminal peptide carboxy functionality to yield a C-terminal
310 cyclopeptide enamide⁶⁰. Non-heme-iron and 2OG-dependent enzymes have been described for the
311 oxidative decarboxylation of amino acid-derived substrates such as tyrosine isonitrile to yield phenol vinyl
312 isonitrile during rhabduscin biosynthesis^{61,62}. Another example of a non-heme-iron and 2OG-dependent
313 enzyme catalyzing decarboxylation-assisted olefin formation is ethylene-forming enzyme which generates
314 ethylene from 2OG⁶³. ZjuDC represents a new enzyme family for peptide oxidative decarboxylation in RiPP
315 biosynthesis (**Figure 1B**). Although ZjuDC shows a low k_{cat} , it could offer a starting point for biocatalytic
316 decarboxylation of cyclic peptides given its solubility from *E. coli* expression and a potential wider substrate
317 scope given its catalytic activity with cyFPIY, and 11 analogs of cyFLXY and cyLLXY substrates. Structural
318 and mechanistic studies of ZjuDC can inform improvements for a broader substrate scope beyond 14-
319 membered macrocycles. The oxidative decarboxylation mechanism of ZjuDC could begin with the activation
320 of dioxygen by the iron cofactor to form a high-valent Fe(IV)-oxo intermediate⁶⁴, similar to other enzymes
321 in this superfamily⁶⁵. Three candidate mechanisms for ZjuDC are presented in **Figure S89** based on
322 different Fe(IV)-oxo intermediates: radical hydroxylation followed by dehydration and decarboxylation,
323 single electron transfer to the substrate leading to a cation, and diradical formation proceeding homolytic
324 cleavage⁶⁶.

325 The final step in the presented biosynthesis of 14-membered CPAs is the α -N-methylation of the
326 decarboxylated CPA intermediate by SAM-dependent ZjuNMT. This methyltransferase also offers
327 biocatalytic access to N-methylated CPAs with reaction products including mono-, di- and tri-N-methylated
328 peptides. The reaction time of ZjuNMT was optimized to reach the highest yields of the desired
329 dimethylation product. The detection of trimethylated products as a ZjuNMT side product analyte *in planta*
330 biosynthesis suggests that *in vitro* reactions might be a more controllable applications of ZjuNMT towards
331 a desired N-methylated CPA. Interestingly, trimethylated N-termini have been reported before in
332 lanthipeptide biosynthesis from marine symbiotic bacteria²⁷. ZjuDC and ZjuNMT are the first characterized
333 enzymes involved in terminal posttranslational modifications of burpitides and represent two diversification
334 strategies of these RiPPs in plants beyond the macrocyclization step⁵² as they accept core peptide
335 substrates with different crosslinking and non-crosslinking residues. A putative N-methyltransferase in CPA
336 biosynthesis was proposed based on *in planta* activity in jujube tissue, which was co-localized with a BURP-
337 domain protein on chromosome 6⁶⁷. Our characterized ZjuNMT is localized on chromosome 4 whereas
338 ZjuDC is localized on chromosome 1. With ZjuBURP and ZjuPrec-FPIY localized on chromosome 9, the
339 described CPA biosynthetic pathway is not entirely clustered on the jujube genome. Further research is
340 needed into the nature and genome location of missing enzymes to complete biosynthesis of 13-membered
341 CPAs such as jubanin K.

342 The characterization of a 14-membered CPA biosynthetic pathway sets up more scalable
343 biosynthesis or chemoenzymatic synthesis of bioactive CPAs such as adouetine X and sanjoinine A for
344 drug development. The introduced enzymes ZjuDC and ZjuNMT further could be explored for biocatalytic
345 decarboxylation and methylation, respectively, of cyclic peptide substrates beyond CPAs^{68,69}. They could
346 also serve as starting points for bioinformatic discovery of homologs in the plant kingdom with different
347 substrate scopes^{52,70}. Ultimately, this work provides a biosynthetic alternative to CPA synthesis for further
348 chemical and biological exploration of these RiPP natural products.

349

350 **Data availability**

351 *Ziziphus jujuba* RNA-seq data has been deposited in the NCBI sequence read archive⁷¹ under Bioproject
352 accession PRJNA1276874. Gene sequences were deposited in GenBank (ZjuBURP - PV929269, ZjuNMT
353 - PV929270, ZjuPrec-FIPFY - PV929271). LC-MS data was deposited to GNPS-MassIVE⁷² under
354 accession MSV000098504 (Password: 4aUgs78Bsvd1V0ar). Synthetic gene sequences used in this study
355 are listed in **Data S2**.

356

357 **Materials and Methods**

358 **Materials**

359 All chemicals and reagents were purchased from Thermo Fisher Scientific Inc. if not otherwise noted. LC-
360 MS solvents were Optima LC-MS-grade solvents (Fisher Scientific Inc.). Sanjoinine A isolated from *Ziziphus*
361 *cambodiana* Pierre. (Cat# HY-119637) was purchased from MedChemExpress. Synthetic gene fragments
362 were obtained from Twist Biosciences Inc. *Ceanothus americanus* dried roots were purchased from
363 Starwest Botanicals. Deoxynucleotide primers were purchased from Integrated DNA Technologies Inc. LC-
364 MS analysis was performed on a Thermo QExactive Orbitrap mass spectrometer coupled to a Vanquish
365 Ultra high performance liquid chromatography instrument. LC-MS analysis was performed on a Thermo
366 QExactive Orbitrap mass spectrometer coupled to a Vanquish Ultra high performance liquid
367 chromatography instrument. LC-MS data was analyzed with QualBrowser from Thermo Xcalibur software
368 package (v4.3.73.11, Thermo Scientific). Preparative and semi-preparative high performance liquid
369 chromatography (HPLC) was performed on a Shimadzu HPLC with two binary LC20-AP pumps, a DGU-
370 403 Degasser, an SPD-20A ultraviolet-visible light detector, and a FRC-10A fraction collector. NMR
371 analysis was done on a Bruker Ascend 800 MHz NMR spectrometer with a 5 mm Triple Resonance Inverse
372 Detection TCI CryoProbe. NMR data was analyzed with MestReNova (v14.0.0, Mestrelab Research).

373

374 **Plant cultivation**

375 *Nicotiana benthamiana* were grown from seeds in Premier Horticulture Pro Mix HP High Porosity with
376 Mycorrhizae for plant growth under plant growth lights with a 16 h light/8 h dark cycle for 4-12 weeks at
377 room temperature. *N. benthamiana* seedlings were transferred after one week to larger pots with the same
378 soil and added Osmocote slow-release fertilizer. Young stem and leaves of *Ziziphus jujuba* Mill. var.
379 Dongzao for RNA-seq and metabolomics were collected on June 6th, 2023 from New Mexico State
380 University Sustainable Agriculture Science Center at Alcalde, NM 87511. The trees are part of the jujube
381 cultivar trial planted in 2015 at Alcalde, NM (lat. 36°05'27.94" N, long. 106°03'24.56" W, elevation, 1730 m).

382

383 **Transcriptomics**

384 Young stem and leaf tissue from shoots of three different *Ziziphus jujuba* trees were frozen in liquid nitrogen
385 and ground with mortar and pestle. Total RNA was isolated from ground plant tissue samples with the
386 QIAGEN RNeasy Plant Mini kit with highest RNA yields in the RLC buffer. RNA-seq library was prepared
387 with NEBNext Poly(A) mRNA Magnetic Isolation Module and the NEBNext Ultra II RNA Library Prep Kit for
388 Illumina. RNA-seq data was generated by Illumina sequencing in paired-end format (2x150 bp) on a
389 NovaSeq 6000 Instrument S4 flow cell (Azenta Genewiz Inc).

390 RNA-seq data analysis was performed on the Great Lakes High-Performance Computing Cluster
391 at the University of Michigan, Ann Arbor. Forward and reverse reads of raw fastq-files were trimmed by
392 TrimGalore (v0.6.7) with default settings and forward and reverse reads of all trimmed files were combined
393 respectively. Combined paired fastq-files were *de novo* assembled by SPAdes (v3.15.5)^{73,74}. The resulting
394 *Ziziphus jujuba de novo* transcriptome fasta file was formatted for BLAST database conversion (truncation
395 of fasta headers <51 letters) and uploaded to an internal Sequenceserver (v3.1.0)⁷⁵ for BLAST+ analysis
396 (v2.16.0)⁴². Target protein sequences such as ZjuPrec-FPIY were queried in the *de novo* transcriptome by
397 tblastn search (v2.16.0) on Sequenceserver (v3.1.0) with the following BLAST parameters: e-value 1e-5,
398 matrix BLOSUM62, gap-open 11, gap-extend 1, filter L. For transcript quantification, kallisto (v0.46.0)⁷⁶ was
399 used to (1) index the combined *de novo Z. jujuba* transcriptome and (2) count transcripts in each RNA-seq
400 dataset. TPM (transcripts per million reads) values were combined for all six samples in a table. For
401 identification of co-expressed genes to a given bait gene, the transcript of a bait gene was determined by
402 tblastn search on Sequenceserver and the identified transcript was used as a bait transcript to calculate
403 Pearson coefficients for TPM values of all other transcripts in the *de novo* transcriptome relative to the TPM
404 values of the bait transcript in Microsoft Excel (2023). Transcripts were then sorted by decreasing Pearson
405 coefficient and the top 131,551 transcripts were generated in a fasta file with seqkit⁷⁷ and annotated with
406 EnTAP (v1.0.0)⁷⁸ using UniProt/SwissProt⁷⁹ as a database. For burpitude cyclase gene search, we searched
407 BURP-domain-containing proteins among the top co-expressed genes relative to *ZjuPrec-FIPFY* transcript.
408 For decarboxylase gene search, we used *ZjuBURP* as a bait gene and searched for co-expressed
409 transcripts encoding annotated oxidative genes such as CYP450s, type III peroxidases, laccases, BURP-
410 domain-containing proteins, and non-heme-iron and 2OG-dependent oxygenases. For *N*-
411 methyltransferase gene discovery, we used *ZjuDC* as a bait gene and searched the top co-expressed
412 transcripts for genes encoding annotated *O*- and *N*-methyltransferases.

413

414 **Pathway elucidation in *Nicotiana benthamiana***

415 Young stem total RNA of *Z. jujuba* was used as a template to generate cDNA with the Thermo Scientific™
416 Maxima H Minus First Strand cDNA Synthesis Kit. *ZjuPrec-FIPFY* was amplified from the young stem *Z.*
417 *jujuba* cDNA by cloning PCR with forward primer tgcccaaattcgcgaccggtATGAAAAGTTTCTTTGCGCTTC
418 and with reverse primer ccagagtaaaggcctcgagTTACTGATGATCAGGAGAAACAAC and cloned via
419 Gibson cloning into pEAQ-HT vector after it was linearized with BshTI (Fisher Scientific) and XhoI (Fisher
420 Scientific). Resulting plasmids were sequenced by Nanopore sequencing (Plasmidsaurus Inc.).

421 Synthetic genes (*ZjuPrec-5xFPIY*, *ZjuBURP*, *ZjuDC* (GenBank: XM_048464910.1), *ZjuNMT*,
422 *ZjuPrec-5xFPIY-ZjuBURP*, *SkrBURP-1xFLLY*, *SkrBURP-1xFLLY..Y*, *SkrBURP-5xFLLY*, *SkrBURP-*
423 *5xFLLY..Y*, *SkrBURP-5xLLIY..F*, *SkrBURP-5xLLxY..F-ACDEF*, *SkrBURP-5xLLxY..F-GHIKL*, *SkrBURP-*
424 *5xLLxY..F-MNPQR*, *SkrBURP-5xLLxY..F-STVWY*, *SkrBURP-5xFLxY..F-ACDEF*, *SkrBURP-5xFLxY..F-*
425 *GHIKL*, *SkrBURP-5xFLxY..F-MNPQR*, *SkrBURP-5xFLxY..F-STVWY*) and cloned genes (*ZjuPrec-FIPFY*)
426 (**Data S2**) were transformed into electrocompetent *Agrobacterium tumefaciens* LBA4404 and clones were
427 selected on sterile YM-agar medium (0.4 g yeast extract, 0.2 g magnesium sulfate heptahydrate, 0.1 g
428 sodium chloride, 0.5 g potassium phosphate (dibasic), adjusted to 1 liter with deionized water) with 50
429 µg/mL rifampicin, 50 µg/mL kanamycin, and 100 µg/mL streptomycin. For small-scale expression
430 experiments, a colony of each construct was transferred into a 5 mL culture of liquid YM medium containing
431 50 µg/mL rifampicin, 50 µg/mL kanamycin, and 100 µg/mL streptomycin. Each culture was grown 24-36 h
432 at 30 °C and 220 rpm and then transferred to a 25 mL culture of liquid YM medium with 50 µg/mL rifampicin,
433 50 µg/mL kanamycin, and 100 µg/mL streptomycin in a 50 mL Bioreactor tube (Cell treat, Cat# 229475)
434 and incubated for 24 h at 30 °C and 220 rpm. *A. tumefaciens* cells were then centrifugated at 3000 x *g* and
435 25 °C and resuspended in MMA medium (10 mM MES (pH 5.6), 10 mM magnesium chloride, 150 µM
436 acetosyringone) to a final OD₆₀₀ of 0.8. For pathway elucidation experiments, resuspensions of *A.*
437 *tumefaciens* cultures of a single gene were combined in equal ratios. Each resuspension or resuspension
438 mixture was incubated for 30 min at 25 °C and then infiltrated with a 1 mL syringe into the bottom of leaves

439 of 4-6 week-old *N. benthamiana* plants. Seven days after infiltration, *N. benthamiana* leaves were collected.
440 For qualitative experiments, 0.3 g of fresh weight transgenic *N. benthamiana* leaves were transferred to an
441 MP Biomedicals Tissuelyzer tube (2 mL, Cat#: 5076200, 5068002) with 10-15 2.3 mm Zirconia silica beads
442 (Cat#: NC0419764), frozen at -80 °C for at least 30 min, and ground in a MP Biomedicals FastPrep-24-5G
443 Tissuelyzer for 60 s at 6 m/s. 1 mL of 80% methanol was added to the ground plant material in the
444 Tissuelyzer tube and ground another 20 s in the Tissuelyzer at 6 m/s. The tubes were then incubated at 60
445 °C for 10 min in a waterbath, centrifugated at 16000 x g at room temperature for 5 min, and the supernatant
446 was filtered with Cytvia syringeless LC-MS filters (UN503NPEORG). The plant methanol extracts were then
447 transferred to LC-MS vials analyzed by LC-MS/MS with the following parameters: LC - Phenomenex
448 Kinetex® 2.6 µm C18 reverse phase 100 Å 150 x 3 mm LC column; LC gradient, solvent A, 0.1% formic
449 acid; solvent B, acetonitrile (0.1% formic acid); 0 min, 10% B; 5 min, 60% B; 5.1 min, 95% B; 6 min, 95% B;
450 6.1 min, 10% B; 9.9 min, 10% B; 0.5 mL/min, 30 °C; MS, positive ion mode; full MS, resolution 70,000; mass
451 range 400–1,200 *m/z*; dd-MS2 (data-dependent MS/MS), resolution 17,500; AGC target 1 x 10⁵, loop
452 count 5, isolation width 1.0 *m/z*, collision energy 25 eV and dynamic exclusion 0.5 s. Sample numbers were
453 *n* = 3 (biological replicates) for each source plant extraction and each transient gene expression experiment
454 in *N. benthamiana*. The negative control of the transient gene expression experiment in *N. benthamiana*
455 was an empty pEAQ-HT vector agroinfiltration experiment. For *Z. jujuba* chemotyping, young stem and leaf
456 tissue samples were prepared and analyzed for LC-MS chemotyping like *N. benthamiana* leaf samples
457 except that stem samples were ground in metal homogenizer tubes with a 0.25 in. steel ball (2 mL, MP
458 Biomedicals, Cat#: MP116991006).

459

460 **Peptide optimization and diversification in transgenic *Nicotiana benthamiana***

461 SkrBURP constructs for peptide optimization (*ZjuPrec-5xFPIY*, *ZjuBURP*, *ZjuPrec-5xFPIY-ZjuBURP-*
462 *fusion*, *SkrBURP-1xFLLY*, *SkrBURP-1xFLLY..Y*, *SkrBURP-5xFLLY*, *SkrBURP-5xFLLY..Y*, *SkrBURP-*
463 *5xLLIY..F*) were expressed transiently in *Nicotiana benthamiana* for 7 days with 4-5 replicates. Infiltrated
464 leaves were frozen at -80 °C and dried by freeze-drying. 50 mg of dried leaves were extracted as described
465 above with 1 mL 80% methanol. Methanol extracts were analyzed as above for peptide chemotyping except
466 for using FullMS mode. Target peptide peak AUC values were characterized in QualBrowser and plotted
467 and analyzed in GraphPad Prism (v10.4.2).

468 SkrBURP constructs for cyFLxY and cyLLxY diversification (*SkrBURP-5xLLxY..F-ACDEF*,
469 *SkrBURP-5xLLxY..F-GHIKL*, *SkrBURP-5xLLxY..F-MNPQR*, *SkrBURP-5xLLxY..F-STVWY*, *SkrBURP-*
470 *5xFLxY..F-ACDEF*, *SkrBURP-5xFLxY..F-GHIKL*, *SkrBURP-5xFLxY..F-MNPQR*, *SkrBURP-5xFLxY..F-*
471 *STVWY*) were expressed transiently in *N. benthamiana* for 7 days with 3 replicates. Samples were prepared
472 from fresh weight tissue as described for peptide chemotyping above. Target cyFLxY and cyLLxY peptides
473 were characterized in QualBrowser based on MS1 and MS2 data. For CPA diversification, each SkrBURP-
474 5xLLxY or SkrBURP-5xFLxY construct was co-expressed with ZjuDC and ZjuNMT transiently in *N.*
475 *benthamiana* for 7 days with 3 replicates. Samples were prepared from fresh weight tissue as described for
476 peptide chemotyping above. Target cyFLxY CPA and cyLLxY CPA peptides were characterized in
477 QualBrowser based on MS1 and MS2 data.

478

479 **Peptide isolation**

480 For scaled production of cyclopeptide alkaloid intermediates cyFPIY, cyFLLY, or cyLLIY, *Agrobacterium*
481 *tumefaciens* LBA4404 was transformed with expression plasmids pEAQ-HT-*ZjuPrec-5xFPIY-ZjuBURP-*
482 *fusion*, pEAQ-HT-*SkrBURP-5xFLLY*, or pEAQ-HT-*SkrBURP-5xLLIY* as described above for pathway
483 expression⁸⁰. A 25 mL YM medium liquid starter culture with 50 µg/mL rifampicin, 50 µg/mL kanamycin,
484 and 100 µg/mL streptomycin was inoculated with a colony of a target gene construct transformant and
485 incubated for 24-36 h at 30 °C and 220 rpm in a 50 mL Bioreactor tube. The culture was then used to
486 inoculate a 1 L YM liquid medium culture with 50 µg/mL rifampicin, 50 µg/mL kanamycin, and 100 µg/mL
487 streptomycin and incubated for 24 h at 30 °C and 220 rpm. The culture was then centrifugated at 3000 x g

488 at 25 °C for 30 min and resuspended in MMA medium to a final OD₆₀₀ of 1.5. 4-8 week-old *Nicotiana*
489 *benthamiana* plants were infiltrated with a transformant of each construct in the bottom leaves by syringe
490 infiltration at scale (total fresh weight: cyFPIY - 1 kg, cyFLLY - 1.1 kg, cyLLIY - 1.2 kg). Transgenic *N.*
491 *benthamiana* leaves were frozen and ground in a food processor. Ground plant material was extracted with
492 methanol (8 L for 1 kg fresh weight plant material) by incubation for 16 h at 37 °C and 160 rpm. Methanol
493 extracts were filtered with a silica filter and dried *in vacuo*. Dried methanol extract of each construct was
494 resuspended in 2 L deionized water and partitioned twice with 2 L hexanes, twice with 2 L of ethyl acetate
495 and finally extracted with 2 L of n-butanol. n-butanol extract of each construct was dried *in vacuo* and
496 separated by Sephadex LH20 (Cytiva, Cat#: 17009001, 300 g) liquid chromatography in a Chemglass 8 x
497 60 cm column, 45/50 (Cat#: CG118931) glass column with a starting mobile phase of 10% methanol. During
498 Sephadex LH20 LC, methanol content of the mobile phase increased by 10% every 500 mL. Sephadex
499 LH20 LC fractions were analyzed for the target cyclic peptide by LC-MS with the following method: Injection
500 volume 2 µL, LC - Phenomenex Kinetex® 2.6 µm C18 reverse phase 100 Å 50 x 3 mm LC column; LC
501 gradient, solvent A, 0.1% formic acid; solvent B, acetonitrile (0.1% formic acid); 0 min: 10% B; 2.5 min: 95%
502 B; 3 min: 95% B; 3.1 min: 10% B; 5 min: 10% B; 0.5 mL/min, 30 °C; MS, positive ion mode; full MS,
503 resolution 70,000; mass range 400–1,200 *m/z*, dd-MS2 (data-dependent MS/MS), resolution 17,500; AGC
504 target 1e5, loop count 5, isolation width 1 *m/z*, collision energy 25 eV and dynamic exclusion 0.5 s. LC
505 fractions with the target peptide were combined, dried *in vacuo*, and subjected to two steps of preparative
506 HPLC with the following parameters: Phenomenex Kinetex® 5 µm C18 100 Å LC Column 150 x 21.2 mm,
507 LC gradients: solvent A – 0.1% trifluoroacetic acid (TFA), solvent B – acetonitrile (0.1% TFA), 1. step: 0
508 min: 10% B, 1 min: 10% B, 36 min: 50% B, 39 min: 95% B, 42 min: 95% B, 42.5 min: 10% B, 60.1 min:
509 10% B. 2. step (cyFPIY): 0 min: 20% B, 1 min: 20% B, 36 min: 40% B, 39 min: 95% B, 42 min: 95% B, 42.5
510 min: 20% B, 60.1 min: 20% B. 2. step (cyFLLY): 0 min: 20% B, 1 min: 20% B, 36 min: 40% B, 39 min: 95%
511 B, 42 min: 95% B, 42.5 min: 20% B, 60.1 min: 20% B. 2. step (cyLLIY): 0 min: 20% B, 1 min: 20% B, 36
512 min: 40% B, 39 min: 95% B, 42 min: 95% B, 42.5 min: 20% B, 60.1 min: 20% B. Preparative HPLC fractions
513 were analyzed for target cyclic peptides as described above. Target peptide fractions were combined and
514 dried *in vacuo*. Each target peptide fraction was subjected to two steps of semipreparative HPLC with the
515 following parameters: Kinetex® 5 µm C18 100 Å LC Column 250 x 10 mm, 1. step: solvent A – 0.1% TFA,
516 solvent B – acetonitrile (0.1% TFA), LC gradient (cyFPIY): 0 min: 25% B, 1 min: 25% B, 21 min: 35% B, 22
517 min: 95% B, 24.5 min: 95%, 25 min: 25% B, 45 min: 25% B. LC gradient (cyFLLY): 0 min: 30% B, 1 min:
518 30% B, 21 min: 40% B, 22 min: 95% B, 24.5 min: 95%, 25 min: 30% B, 45 min: 30% B, LC gradient (cyLLIY):
519 0 min: 29% B, 1 min: 29% B, 21 min: 34% B, 22 min: 95% B, 24.5 min: 95%, 25 min: 29% B, 45 min: 29%
520 B. 2. step: solvent A – 0.1% TFA, solvent B – methanol (0.1% TFA), LC gradient (cyFPIY): 0 min: 40% B,
521 1 min: 40% B, 21 min: 60% B, 22 min: 95% B, 24.5 min: 95%, 25 min: 40% B, 45 min: 40% B. LC gradient
522 (cyFLLY): 0 min: 58% B, 1 min: 58% B, 21 min: 58% B, 22 min: 95% B, 24.5 min: 95%, 25 min: 58% B, 45
523 min: 58% B. LC gradient (cyLLIY): 0 min: 57% B, 1 min: 57% B, 21 min: 57% B, 22 min: 95% B, 24.5 min:
524 95%, 25 min: 57% B, 45 min: 57% B. Semipreparative HPLC fractions were analyzed for target cyclic
525 peptides as described above. Target peptide fractions were combined and dried *in vacuo*. cyFPIY (5 mg)
526 was a white powder, cyFLLY (4.5 mg) was a white powder, cyLLIY (6.7 mg) was a white powder.

527

528 **Stereochemical analysis**

529 About 400 µg of each purified cyclopeptide alkaloid was hydrolyzed in 600 µL of 6 M HCl in a sealed thick-
530 walled reaction vessel⁸¹. The sample was heated at 110 °C and stirred overnight for 12 h. Subsequently,
531 the hydrolysate was concentrated to dryness under nitrogen gas and redissolved in 100 µL water. Then,
532 100 µL of 1 M NaHCO₃ and 100 µL of a 1% acetone solution of 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide
533 (L-FDAA) were added to the solution. The reaction mixture was incubated at 40 °C for 1 h and then
534 quenched by adding 100 µL of 1 M HCl. For the preparation of L-FDAA-amino acid standard derivatives,
535 50 mM of each amino acid (D/L-Phe, D/L-Pro, D/L-Ile, D/L-*allo*-Ile, D/L-Leu and D/L-Tyr) dissolved in water
536 (50 µL) was treated with 1 M NaHCO₃ (20 µL) and 1% I-FDAA (100 µL) at 40 °C for 1 h, respectively. After

537 the reaction, the solution was quenched with 1 M HCl (20 μ L) and diluted with acetonitrile (810 μ L) for LC-
538 MS analysis. LC-MS/MS analysis parameters were as follows: injection volume 2 μ L; LC, Phenomenex
539 Kinetex 2.6 μ m C18 reverse phase 100 \AA 150 x 3 mm LC column; LC gradient: solvent A, 0.1% formic acid;
540 solvent B, acetonitrile (0.1% formic acid); 0 min, 10% B; 40 min, 60% B; 41 min, 95% B; 44 min, 95% B;
541 45 min, 10% B, 50 min, 10% B, 0.5 mL/min, 30 $^{\circ}$ C; MS, positive ion mode; full MS, resolution 70,000, mass
542 range 100–1,000 m/z .

543 To determine the configuration of Ile, the C3-Marfey's method was employed⁸². Hydrolysis and
544 derivatization were conducted as described above, with the analytical conditions modified as follows:
545 injection volume 5 μ L; LC, Agilent Zorbax StableBond C3 5 μ m 150 x 4.6 mm LC column; LC gradient:
546 solvent A, Water with 5% acetonitrile and 0.05% formic acid; solvent B, methanol with 5% acetonitrile and
547 0.05% formic acid; 0 min, 15% B; 53 min, 60% B; 54 min, 95% B; 59 min, 95% B; 60 min, 15% B, 70 min,
548 15% B, 0.7 mL/min, 50 $^{\circ}$ C; MS, positive ion mode; full MS, resolution 70,000, mass range 100–1,000 m/z .
549 The configurations of the amino acid residues were determined by comparing their retention times with
550 those of FDAA derivatives of amino acid standards.

551 To determine the configuration of PheNMe₂ and LeuNMe₂, PGME derivatization was performed⁴¹.
552 Hydrolysis was carried out as described for Marfey's analysis. After hydrolysis, the resulting peptide was
553 dissolved in anhydrous tetrahydrofuran (1 mL), to which (S)-(+)-2-phenylglycine methyl ester (PGME, 2 mg)
554 was added. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide (EDC, 1.2 μ L) was then added, and the
555 reaction mixture was stirred at 25 $^{\circ}$ C for 2 h. The reaction was quenched by the addition of methanol
556 (500 μ L), concentrated under a stream of nitrogen, and the residue was redissolved in methanol (1 mL).
557 For the preparation of PGME-amino acid standard derivatives, D-/L-PheNMe₂ and D-/L-LeuNMe₂ (1 mg
558 each) were dissolved in anhydrous tetrahydrofuran (1 mL). To each solution, (S)-(+)-2-phenylglycine methyl
559 ester (PGME, 2 mg) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC, 1.2 μ L) were added. The
560 reaction mixtures were stirred at 25 $^{\circ}$ C for 2 h, quenched by addition of methanol (500 μ L), concentrated
561 under a stream of nitrogen, and the residues were redissolved in methanol (1 mL) for LC-MS analysis. LC-
562 MS/MS analysis parameters: injection volume 5 μ L; LC, Phenomenex Kinetex 2.6 μ m C18 reverse phase
563 100 \AA 150 x 3 mm LC column; LC gradient: solvent A, 0.1% formic acid; solvent B, acetonitrile (0.1% formic
564 acid); 0 min, 10% B; 40 min, 50% B; 41 min, 95% B; 44 min, 95% B; 45 min, 10% B, 50 min, 10% B,
565 0.5 mL/min, 30 $^{\circ}$ C; MS, positive ion mode; full MS, resolution 70,000, mass range 100–1,000 m/z .

566

567 **Jubanine K isolation**

568 Dried stems of *Ziziphus jujuba* (2.5 kg) were ground into powder and extracted with methanol (8 L) at 37 $^{\circ}$ C
569 with shaking at 160 rpm for 16 h. The crude extract was resuspended in 2 L of deionized water, and the pH
570 was adjusted to 2.5 using 2 M HCl. The acidified aqueous phase was extracted with ethyl acetate (3 x 2 L),
571 and the organic layers were discarded to remove non-target components. The aqueous phase was then
572 basified to pH 9.5 using 2 M NaOH and subsequently extracted with chloroform (3 x 2 L). The combined
573 chloroform extracts were concentrated under reduced pressure to afford a residue for further purification.
574 The chloroform fraction was subjected to Sephadex LH20 chromatography (60 x 8 cm) using a 1:1 mixture
575 of dichloromethane and methanol. Fractions were analyzed by LC-MS with the following parameters:
576 injection volume, 2 μ L; column, Phenomenex Kinetex[®] 2.6 μ m C18 100 \AA (50 x 3 mm); solvent A, 0.1%
577 formic acid in water; solvent B, acetonitrile (0.1% formic acid); 0.5 mL/min, 30 $^{\circ}$ C; gradient: 0 min, 5% B;
578 2.5 min, 95% B; 3.0 min, 95% B; 3.1 min, 5% B; 5.0 min, 5% B. MS settings: positive ion mode; full MS
579 resolution, 35,000; mass range, 400–1,200 m/z ; dd-MS² resolution, 17,500; collision energy, 25 eV;
580 dynamic exclusion, 0.5 s. Jubanine K-containing fractions were combined and then separated by one round
581 of preparative HPLC and one round of semipreparative HPLC with the following LC condition: PrepHPLC:
582 Phenomenex Kinetex[®] 5 μ m C18 100 \AA LC Column 150 x 21.2 mm, solvent A - 0.1% TFA in water, solvent
583 B - acetonitrile (0.1% TFA), LC gradients: 7.5 mL/min, 0 min: 10% B, 1 min: 10% B, 36 min: 70% B, 39 min:
584 95% B, 42 min: 95% B, 42.5 min: 10% B, 60.1 min: 10% B. SemiprepHPLC: Kinetex[®] 5 μ m C18 100 \AA
585 250 x 10 mm column, solvent A - 0.1% TFA, solvent B - acetonitrile (0.1% TFA), 1.5 mL/min, 0 min - 43%

586 B, 1 min - 43% B, 21 min - 48% B, 22 min - 95% B, 25 min - 95% B, 25.1 min - 20% B, 45 min - 20% B.
587 Jubanine K (1.7 mg) was obtained as a white amorphous powder.

588

589 **ZjuDC Expression and Purification**

590 *E. coli* BL21 (DE3) was transformed with codon-optimized pHis₈-ZjuDC (pHis₈ is pET28a with an N-terminal
591 His₈-tag, cleavable by tobacco etch virus (TEV) protease, **Data S2**) by heat shock and plated on Luria-
592 Bertani (LB)-agar plates with 50 µg/mL kanamycin. A colony was used to inoculate a 10 mL starter culture
593 of LB with 50 µg/mL kanamycin. Starter cultures grew aerobically overnight at 37°C, 200-250 rpm in a
594 shaking incubator. The starter was then used to inoculate 1L of sterile Terrific Broth in a 2.8 L Fernbach
595 flask. Large-scale cultures grew at 37 °C, 200-250 rpm, until absorbance (OD₆₀₀) reached 0.4-0.7. The
596 flasks continued shaking as the temperature was lowered to 18 °C. At 18-20 °C the OD₆₀₀ was 0.6-1.0, and
597 cultures were induced with 50 µM IPTG and grown overnight.

598 The contents were centrifuged at 4,000 x g, 4 °C for 30 min. The supernatant was discarded, and
599 cell pellets were resuspended in 5 mL lysis buffer (50 mM Tris-HCl pH 8, 500 mM NaCl, 1% Tween-20,
600 10% glycerol, 10 mM imidazole, and 10 mM β-mercaptoethanol) per gram of wet cell pellet. Lysozyme was
601 added in a ratio of 0.5 mg per mL of lysate, then, ~10 U of DNaseI was added. Contents stirred at 4 °C for
602 1 h, then sonicated on ice for eight, 1 min pulses of 80% amplitude, 2 s on, 2 s off. The lysate was
603 centrifuged at 19,500 x g, 4 °C for 45 min. The clarified lysate was purified by gravity flow immobilized metal
604 affinity chromatography (IMAC) at 4°C. Ni-NTA resin, 2 mL, was added to a 20 mL disposable column (Bio-
605 Rad) and equilibrated with 10 CV of lysis buffer. Clarified lysate was poured over the resin and the flow
606 through was discarded. The resin was washed for 10 CV with wash buffer (50 mM Tris-HCl pH 8, 500 mM
607 NaCl, 10% glycerol, 30 mM imidazole, and 10 mM β-mercaptoethanol) and eluted with 5 CV of elution
608 buffer with 300 mM imidazole pH 8. The eluted protein was added to 3.5 kDa MWCO dialysis tubing for
609 dialysis in 50 mM HEPES pH 7.5, 100 mM NaCl, 3 mM reduced glutathione (GSH), and 0.3 mM oxidized
610 glutathione (GSSG) with stirring at 4 °C overnight. Following dialysis, the protein was concentrated in
611 Amicon Ultra-15 mL 10 kDa MWCO centrifugal concentrators (Millipore Sigma) before size-exclusion
612 chromatography (SEC) and subsequent use in assays.

613 ZjuDC was further purified by SEC on a Cytiva HiLoad 26/600 Superdex 200 prep grade column
614 precalibrated with the manufacturer's kit (Cytiva) on an ÄKTA Fast Protein Liquid Chromatography system
615 (FPLC) at 4-8 °C. ZjuDC was eluted 50 mM HEPES pH 7.5, 100 mM NaCl in 2 mL fractions. ZjuDC eluted
616 as a monomer with an apparent molecular weight of 35 kDa. Fractions eluting as a monomer were >95%
617 pure by SDS-PAGE (**Figure S25**), then pooled and concentrated using an Amicon Ultra-15 mL 10 kDa
618 MWCO centrifugal concentrator for enzyme assays. SDS-PAGE was imaged with Google Pixel 8 and
619 annotated in PowerPoint (Microsoft, 2023). The protein concentration was estimated by OD₂₈₀ using a
620 Thermo Scientific NanoDrop One microvolume ultraviolet-visible light spectrophotometer based on the
621 calculated ExpASy ProtParam extinction coefficient⁸³. The yield for ZjuDC following purification and SEC
622 ranged from 15-18 mg monomer per L of culture.

623

624 **Anaerobic *in vitro* reconstitution assay for ZjuDC**

625 Assays were handled in a Vacuum Atmospheres, Inc. anaerobic chamber (Ragsdale laboratory, University
626 of Michigan, Ann Arbor) containing <1 ppm O₂. Buffers were 0.2 µm filtered and degassed with nitrogen
627 prior to use in the anaerobic chamber. ZjuDC was buffer exchanged in the chamber with 50 mM HEPES
628 pH 7.5, 100 mM NaCl (Amicon Ultra Centrifugal Filter, 10 kDa MWCO) before addition to assays. Assays
629 were 50 µL total volume with final concentrations of 50 mM HEPES pH 7.5, 200 µM FeSO₄-7H₂O, 500 µM
630 2-oxoglutarate (Chem-Impex Int'l Inc.), 400 µM L-ascorbic acid sodium salt (Acros Organics), 4% dimethyl
631 sulfoxide, and 90 µM cyFPiY substrate. Control assays were quenched with a final concentration of 555
632 mM formic acid for 0.5 h prior to ZjuDC enzyme addition (5 µM final concentration). The pH of the assay
633 solution dropped from 7.40 to 2.56 in the presence of formic acid. Experimental assays had 5 µM ZjuDC
634 added and were only quenched with the same concentration of formic acid prior to removal from the

635 chamber. All assays were done in quadruplicate and incubated in the chamber for 26 h at 21-24 °C. The
636 same stock solutions, final concentrations, controls, and experimental assays were replicated in triplicate
637 in the presence of O₂ in the Kersten lab. The O₂ containing samples were incubated for 24 h at 21-24 °C
638 prior to analysis.

639 The reaction mixtures were analyzed by LC-MS with the following settings: 5 µL injection volume
640 on a Kinetex 2.6 µm C18 100Å 150 x 3 mm column, where solvent A is 0.1% formic acid in water and
641 solvent B is 100 % acetonitrile with 0.1% formic acid, a 0.5 mL/min flow rate and 30 °C column chamber.
642 The LC gradient was as follows: 0 min: 10 % B, 0.7 min: 10 % B, 5.7 min: 60% B, 5.8 min: 95% B, 6.7 min:
643 95% B, 6.8 min: 10% B, 10.6 min: 10% B. MS was run in positive ion mode with Full MS: resolution 35,000,
644 mass range *m/z* 300-1200, AGC target 1e6, and maximum IT 50 ms. The dd-MS2 settings were as follows:
645 resolution 17,500, AGC target 1e5, maximum IT 50 ms, loop count 5, isolation window *m/z* 1, and
646 (N)CE/stepped NCE 20, 25, 30 eV. MS data of cyFPIY (*m/z* 537.2708, *z*=1) and cyFPIY-dc (*m/z* 491.2653,
647 *z*=1) were analyzed manually with Qualbrowser. We observe less than 1% of hydroxylated cyFPIY (*m/z*
648 553.2662, *z*=1) in our replicates.

649 The positive controls for dioxygen-containing assays were also tested via LC-MS/MS for succinate
650 production, along with a standard of 100 µM succinic acid. The assays and standard were analyzed by LC-
651 MS with the following settings: 5 µL injection volume on a Kinetex 2.6 µm C18 100Å 150x3 mm column,
652 where solvent A is 20 mM ammonium formate pH 3.2 in water and solvent B is 90 % acetonitrile with 10%
653 ammonium formate, a 0.5 mL/min flow rate and 30 °C column chamber. The LC gradient was as follows: 0
654 min: 0 % B, 5.0 min: 40% B, 5.1 min: 95% B, 6.0 min: 95% B, 6.1 min: 0% B, 9.9 min: 0% B. MS was run
655 in negative ion mode with Full MS: resolution 35,000, mass range *m/z* 50-500, AGC target 1e6, and
656 maximum IT 50 ms. The dd-MS2 settings were as follows: resolution 17,500, AGC target 1e5, maximum IT
657 50 ms, loop count 5, isolation window *m/z* 1, and (N)CE/stepped NCE 20, 25, 30 eV.

658
659 **ZjuDC Steady State Kinetics**

660 End point assays were 50 µL total volume containing final concentrations of 50 mM HEPES pH 7.5, 0.5 µM
661 ZjuDC, 20 µM FeSO₄·7H₂O, 500 µM 2-oxoglutarate, 400 µM L-ascorbic acid sodium salt, and 4 % DMSO
662 to maintain solubility of cyFPIY. The initial velocity of ZjuDC-catalyzed styrylamine formation was monitored
663 by discontinuous LC-MS/MS-based assays. Nine concentrations of cyFPIY, 0.25, 0.50, 1.0, 2.0, 3.5, 5, 7.5,
664 10, and 15 µM, were incubated at room temperature and quenched with 100% methanol after 30 sec, 2
665 min, 4min, 6 min, 8 min, and 10 min to generate an initial rate. Each substrate concentration and time point
666 was conducted in quadruplets. All assays were analyzed by LC-MS with the following settings: 5 µL injection
667 volume on a Kinetex 2.6 µm C18 100Å 150x3 mm column, where solvent A is 0.1% formic acid in water
668 and solvent B is 100 % acetonitrile with 0.1% formic acid, a 0.5 mL/min flow rate and 30 °C column chamber.
669 The LC gradient was as follows: 0 min: 10 % B, 5.7 min: 60% B, 5.8 min: 95% B, 6.7 min: 95% B, 6.8 min:
670 10% B, 10.6 min: 10% B. MS was run in positive ion mode with Full MS: resolution 35,000, mass range *m/z*
671 300-1,200, AGC target 1e6, and maximum IT 50 ms. The dd-MS2 settings were as follows: resolution
672 17,500, AGC target 1e5, maximum IT 50 ms, loop count 5, isolation window *m/z* 1, and (N)CE/stepped
673 NCE 20, 25, 30 eV. MS data of cyFPIY-dc (*m/z* 491.2653, *z*=1) was analyzed manually with Qualbrowser.

674 The substrate cyFPIY and product cyFPIY-dc were quantified using corresponding MS1 extracted
675 ion chromatograms (EIC) peak areas normalized to total detected EIC peak areas. EIC peak areas were
676 determined by peak integration in QualBrowser and were further analyzed and plotted in GraphPad Prism.
677 Product formation was converted to µM by calculating percent product formation through area under the
678 curve and then using that percentage to calculate product concentration from the known substrate
679 concentration added to the assays. The *k*_{cat} and *K*_M values were determined by fitting the initial velocity data
680 using the equation $V_0 = V_{max}[S]/(K_M + [S])$ where *V*₀ is the initial velocity, *V*_{max} is the maximal velocity, [S] is
681 the concentration of substrate, and *K*_M is the Michaelis constant. Substrate inhibition occurred when
682 ascorbate and 2-oxoglutarate concentrations were 4 mM and 5 mM, respectively.

683

684 **ZjuDC enzyme assays**

685 *In vitro* enzyme assays were 50 μ L total volume containing 50 mM HEPES pH 7.5, 5 μ M ZjuDC, 100 μ M
686 cyFPIY, 200 μ M FeSO₄·7H₂O, 500 μ M 2-oxoglutarate, 400 μ M L-ascorbic acid sodium salt, and 4% dimethyl
687 sulfoxide (DMSO) maintain solubility of cyFPIY. cyFPIY was dissolved in 100% DMSO and added to
688 enzyme assays for a total of 4% DMSO in the assay. All assays conducted for the cofactor/substrate screen
689 contained 50 mM HEPES pH 7.5, 5 μ M ZjuDC, 90 μ M cyFPIY, and 400 μ M L-ascorbic acid sodium salt
690 where the 200 μ M FeSO₄·7H₂O and 500 μ M 2-oxoglutarate were added back in respectively. It was later
691 determined that ascorbate was not required for ZjuDC activity. Negative control assays were performed
692 with ZjuDC that had been boiled at 95 °C for 20 min while maintaining the same conditions described. All
693 assays were done in triplicates and incubated at 30 °C for 24 h before quenching with an equal volume of
694 100 % methanol. Quenched assays were then centrifuged at 16,200 x g for 5 min to pellet precipitate. The
695 resulting supernatant was collected for analysis.

696 The assays were analyzed by LC-MS with the following settings: 5 μ L injection volume on a Kinetex
697 2.6 μ m C18 100Å 150x3 mm column, where solvent A is 0.1% formic acid in water and solvent B is 100 %
698 acetonitrile with 0.1% formic acid, a 0.5 mL/min flow rate and 30 °C column chamber. The LC gradient was
699 as follows: 0 min: 10 % B, 0.7 min: 10 % B, 5.7 min: 60% B, 5.8 min: 95% B, 6.7 min: 95% B, 6.8 min: 10%
700 B, 10.6 min: 10% B. MS was run in positive ion mode with Full MS: resolution 35,000, mass range *m/z* 300-
701 1,200, AGC target 1e6, and maximum IT 50 ms. The dd-MS2 settings were as follows: resolution 17,500,
702 AGC target 1e5, maximum IT 50 ms, loop count 5, isolation window *m/z* 1, and (N)CE/stepped NCE 20,
703 25, 30 eV. MS data of cyFPIY (*m/z* 537.2708, *z*=1) and cyFPIY-dc (*m/z* 491.2653, *z*=1) were analyzed
704 manually with Qualbrowser.

705

706 **Scaled *in vitro* formation of cyFPIY-dc**

707 The assay was 10 mL in total volume containing final concentrations of 50 mM HEPES pH 7.5, 19.5 μ M
708 ZjuDC, 390 μ M cyFPIY, 780 μ M FeSO₄·7H₂O, 1.95 mM 2-oxoglutarate, 1.56 mM L-ascorbic acid sodium
709 salt, and 4 % DMSO to maintain solubility of cyFPIY. cyFPIY (9832 μ M, 3.2 mg total) was dissolved in 100%
710 DMSO prior to use. The reaction was incubated at 30°C for 24 h and quenched with equal volume of 100%
711 methanol. Contents were centrifuged at 4000 x g for 10 min to pellet precipitate. The resulting supernatant
712 was dried *in vacuo* and extracted four times with 25 mL of ethyl acetate. The organic layer was kept, dried
713 *in vacuo*, and resuspended in 30% acetonitrile for semi preparative HPLC purification with the following LC
714 settings: Kinetex® 5 μ m C18 100 Å 250 × 10 mm column, solvent A - 0.1% TFA, solvent B - acetonitrile
715 (0.1% TFA), 1.5 mL/min, 0 min - 35% B, 1 min - 35% B, 21 min - 40% B, 22 min - 95% B, 25 min - 95% B,
716 25.1 min - 35% B, 45 min - 35% B. cyFPIY-dc (**2**) was obtained as a white powder (2.9 mg) and stored at -
717 80 °C for later use with enzyme assays.

718

719 **ZjuNMT expression and purification**

720 The expression and purification of His₈-ZjuNMT (**Data S2**) followed the same protocol described for ZjuDC
721 with a slight deviation in the buffer used in dialysis prior to assays. After IMAC elution, ZjuNMT was added
722 to 3.5 kDa MWCO dialysis tubing for dialysis in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 3 mM GSH, and 0.3
723 mM GSSG with stirring at 4 °C overnight. After dialysis, the protein was concentrated in Amicon Ultra-15
724 mL 10 kDa MWCO centrifugal concentrators and stored at -80°C for later use with enzyme assays.

725

726 **ZjuNMT enzyme Assays**

727 Both cyFPIY and cyFPIY-dc were used in enzyme assays to test for promiscuity of ZjuNMT. *In vitro* enzyme
728 assays were 50 μ L total volume containing 50 mM Tris-HCl pH 8.0, 10 μ M ZjuNMT, 100 μ M cyFPIY or 100
729 μ M cyFPIY-dc, and 1 mM S-adenosylmethionine (SAM). Stocks of cyFPIY-dc and cyFPIY were dissolved
730 in 100% DMSO and added to enzyme assays for a total of 4% DMSO in the assay. The cofactor screen
731 contained 50 mM Tris-HCl pH 8, 10 μ M ZjuNMT, and 100 μ M cyFPIY without SAM. Negative control assays
732 were performed with ZjuNMT that boiled at 95 °C for 20 min while maintaining the same conditions with

733 cyFPIY-dc as described. All assays were done in triplicates and incubated at 30 °C for 24 h before
734 quenching with an equal volume of 100 % methanol. Time course assays were conducted under the same
735 conditions described and incubated at 30 °C for 10 min, 30 min, 1 h, 2 h, and 4 h being quenched with an
736 equal volume of 100% methanol. Quenched assays were then centrifuged using a at 16,200 x g for 5 min
737 to pellet precipitate. The resulting supernatant was collected for analysis.

738 The assays were analyzed by LC-MS with the following settings: 5 µL injection volume on a Kinetex
739 2.6 µm C18 100Å 150 x 3 mm column, where solvent A is 0.1% formic acid in water and solvent B is 100
740 % acetonitrile with 0.1% formic acid, a 0.5 mL/min flow rate and 30 °C column chamber. The LC gradient
741 was as follows: 0 min: 10 % B, 0.7 min: 10 % B, 5.7 min: 60% B, 5.8 min: 95% B, 6.7 min: 95% B, 6.8 min:
742 10% B, 10.6 min: 10% B. MS was run in positive ion mode with Full MS: resolution 35,000, mass range m/z
743 300-1,200, AGC target 1e6, and maximum IT 50 ms. The dd-MS2 settings were as follows: resolution
744 17,500, AGC target 1e5, maximum IT 50 ms, loop count 5, isolation window m/z 1, and (N)CE/stepped
745 NCE 20, 25, 30 eV. MS data of cyFPIY-dc (m/z 491.2653, $z=1$), Lotusine A (m/z 519.2966, $z=1$), and *N,N*-
746 Me₂-cyFPIY (m/z 565.3021, $z=1$) were analyzed manually with Qualbrowser.

747

748 **Scaled *in vitro* formation of Lotusine A**

749 *In vitro* lotusine A reaction was 13 mL total volume, aliquoted in 250 µL reactions. Each 250 uL volume
750 contained a final concentration of 50 mM Tris-HCl pH 8.0, 10 µM ZjuNMT, 100 µM cyFPIY-dc (total 2.6
751 mg), 4 % DMSO to maintain solubility of cyFPIY-dc, and 1 mM SAM. The reactions were incubated at 30°C
752 for 30 min and quenched with equal volume of 100% methanol. After 30 min of incubation, an increase in
753 trimethylation occurred. Reaction contents were centrifuged at 16,200 x g for 5 min to pellet precipitate.
754 The supernatants were pooled, dried *in vacuo*, and resuspended in 30% acetonitrile for semipreparative
755 HPLC purification with the following LC settings: Kinetex® 5 µm C18 100 Å 250 x 10 mm column, solvent A
756 - 0.1% TFA, solvent B - acetonitrile (0.1% TFA), 1.5 mL/min, 0 min - 35% B, 1 min - 35% B, 21 min - 40%
757 B, 22 min - 95% B, 25 min - 95% B, 25.1 min - 35% B, 45 min - 35% B. Lotusine A was obtained as a white
758 amorphous powder (2.2 mg).

759

760 **One pot formation of sanjoinine A and adouetine X**

761 One pot enzyme assays were 50 µL in total volume containing final concentrations of 50 mM HEPES pH
762 7.5, 10 µM ZjuDC, 10 µM ZjuNMT, 25 µM substrate, 200 µM FeSO₄·7H₂O, 500 µM 2-oxoglutarate, 400 µM
763 L-ascorbic acid sodium salt, 1 mM SAM, and 4% dimethyl sulfoxide (DMSO) to maintain solubility of
764 substrates. The substrates were cyFLLY and cyLLIY, each was dissolved in 100% DMSO and added to
765 enzyme assays for a total of 4% DMSO. Assays were incubated for 1, 2, 4, 8, 16, and 24 h at 30 °C and
766 quenched with equal volume of 100% methanol. Quenched assays were centrifuged at 16,200 x g for 5
767 min to pellet precipitate. The resulting supernatant was collected for product formation analysis.

768 The assays were analyzed by LC-MS with the following settings: 5 µL injection volume on a Kinetex
769 2.6 µm C18 100Å 150 x 3 mm column, where solvent A is 0.1% formic acid in water and solvent B is 100
770 % acetonitrile with 0.1% formic acid, a 0.5 mL/min flow rate and 30 °C column chamber. The LC gradient
771 was as follows: 0 min: 10 % B, 0.7 min: 10 % B, 5.7 min: 60% B, 5.8 min: 95% B, 6.7 min: 95% B, 6.8 min:
772 10% B, 10.6 min: 10% B. MS was run in positive ion mode with Full MS: resolution 35,000, mass range m/z
773 300-1,200, AGC target 1e6, and maximum IT 50 ms. The dd-MS2 settings were as follows: resolution
774 17,500, AGC target 1e5, maximum IT 50 ms, loop count 5, isolation window m/z 1, and (N)CE/stepped
775 NCE 20, 25, 30 eV. MS data of sanjoinine A (m/z 535.3279, $z=1$) and adouetine X (m/z 501.3435, $z=1$)
776 were analyzed manually with Qualbrowser, and compared to authentic standards.

777

778 **Molecular Networking analysis for Cyclopeptide Alkaloids**

779 For cyclopeptide alkaloid chemotyping, metabolomic datasets from Matthaei botanical garden (MassIVE-
780 GNPS accession MSV000087872) and from *Ziziphus jujuba* stem and leaf samples of this study were
781 filtered for analytes with iminium ion masses of unmethylated, monomethylated and dimethylated

782 proteinogenic amino acids^{11,80} with MassQL⁸⁴ (v31.4) with the following command: QUERY
783 scaninfo(MS2DATA) WHERE MS2PROD=(58.06513 OR 60.04439 OR 70.06513 OR 72.08078 OR
784 74.06004 OR 84.04439 OR 84.08078 OR 86.09643 OR 87.05529 OR 88.0393 OR 88.07569 OR 100.11208
785 OR 101.07094 OR 101.10732 OR 102.05495 OR 102.09134 OR 104.05285 OR 110.07127 OR 114.12773
786 OR 115.08659 OR 115.12297 OR 116.0706 OR 118.0685 OR 120.08078 OR 124.08692 OR 129.10224
787 OR 129.11347 OR 129.13862 OR 130.08625 OR 132.08415 OR 134.09643 OR 136.07569 OR 138.10257
788 OR 143.12912 OR 148.11208 OR 150.09134 OR 157.14477 OR 159.09167 OR 164.10699 OR 173.10732
789 OR 187.12297):TOLERANCEPPM=10:INTENSITYPERCENT= 5. From the MassQL-filtered mass spectra
790 and tandem mass spectra of CPA standards (sanjoinine A, adouetine X, selanine A, jubanine K), a
791 molecular network was created using the online workflow ([https://ccms-
792 ucsd.github.io/GNPSDocumentation/](https://ccms-ucsd.github.io/GNPSDocumentation/)) on the GNPS website (<http://gnps.ucsd.edu>)⁷². The data was filtered
793 by removing all MS/MS fragment ions within +/- 17 Da of the precursor *m/z*. MS/MS spectra were window
794 filtered by choosing only the top 6 fragment ions in the +/- 50 Da window throughout the spectrum. The
795 precursor ion mass tolerance was set to 0.05 Da and a MS/MS fragment ion tolerance of 0.05 Da. A network
796 was then created where edges were filtered to have a cosine score above 0.7 and more than 6 matched
797 peaks. Further, edges between two nodes were kept in the network if and only if each of the nodes appeared
798 in each other's respective top 10 most similar nodes. Finally, the maximum size of a molecular family was
799 set to 500, and the lowest scoring edges were removed from molecular families until the molecular family
800 size was below this threshold. The spectra in the network were then searched against GNPS' spectral
801 libraries. The library spectra were filtered in the same manner as the input data. All matches kept between
802 network spectra and library spectra were required to have a score above 0.7 and at least 6 matched peaks.
803 The molecular network was analyzed for the main CPA cluster and visualized by Cytoscape (v3.10.3)⁸⁵.

804

805 **Acknowledgements**

806 This study was supported by NIGMS (grant R35GM146934 to R.D.K., grant F32GM146395 to L.S.M., grant
807 F31GM155959 to K.S., Pharmacological Sciences Training Program predoctoral fellowship T32GM140223
808 to D.O.), the Hermann Frasch Foundation (R.D.K.), a Rackham Merit Fellowship (D.O.), the PhRMA
809 foundation (predoctoral fellowship, D.N.C.), and the USDA Specialty Crop Block Grant Program through
810 the New Mexico Department of Agriculture (S.Y.). We thank Dr. George Lomonosoff (John Innes Centre,
811 UK) for sharing the pEAQ-HT vector. This research was supported in part through computational resources
812 and services provided by Advanced Research Computing at the University of Michigan, Ann Arbor. We
813 thank Dr. Stephen Ragsdale for anaerobic chamber access and Kareem Aboulhosn for assistance, Dr.
814 Emily Scott for Fast Protein Liquid Chromatography use, and Dr. Janet Smith and Dr. Graham Moran for
815 helpful discussions.

816

817 **Author Contributions:** R.D.K. conceived the idea. J.H., R.D.K. performed bioinformatic analysis for
818 biosynthetic gene identification and *in planta* characterization of biosynthetic genes. J.H., X.W. and R.D.K.
819 purified and characterized peptide natural products from source and transgenic plants. J.H. and L.S.M.
820 performed enzyme assays. J.H, D.O., X.W., K.S., D.N.C., G.M., W.L., L.S.M, K.M.M. performed scaled
821 tobacco infiltration and peptide purification. L.M.P. performed SkrBURP metabolic engineering. S.Y.
822 cultivated source plants. J.H., L.S.M., X.W. and R.D.K. wrote the manuscript. All authors have read and
823 approved the manuscript.

824

825 **Competing Interest Statement:** The authors declare no competing interests.

826

827 **Keywords:** cyclopeptide alkaloid, burpitide, RiPP, natural products

828

829 **References**

830 1. Tschesche, R. & Kaußmann, E. U. Chapter 4 the cyclopeptide alkaloids. in *Chemistry and Physiology*

- 831 165–205 (Elsevier, 1975).
- 832 2. Structures Of Adouetines, X. & The Alkaloids Of Waltheria Americana, Z. Y1, and Z, the Alkaloids of
833 Waltheria Americana L.
- 834 3. Trevisan, G. *et al.* Antinociceptive effects of 14-membered cyclopeptide alkaloids. *J. Nat. Prod.* **72**,
835 608–612 (2009).
- 836 4. Han, H. *et al.* Anxiolytic-like effects of sanjoinine A isolated from Zizyphi Spinosi Semen: possible
837 involvement of GABAergic transmission. *Pharmacol. Biochem. Behav.* **92**, 206–213 (2009).
- 838 5. Kang, K. B. *et al.* Jubanines F–J, cyclopeptide alkaloids from the roots of Ziziphus jujuba.
839 *Phytochemistry* **119**, 90–95 (2015).
- 840 6. Tan, N.-H. & Zhou, J. Plant cyclopeptides. *Chem. Rev.* **106**, 840–895 (2006).
- 841 7. Chekan, J. R., Mydy, L. S., Pasquale, M. A. & Kersten, R. D. Plant peptides – redefining an area of
842 ribosomally synthesized and post-translationally modified peptides. *Nat. Prod. Rep.* (2024)
843 doi:10.1039/d3np00042g.
- 844 8. Gulder, T. & Baran, P. S. Strained cyclophane natural products: macrocyclization at its limits. *Nat.*
845 *Prod. Rep.* **29**, 899–934 (2012).
- 846 9. Wang, Y. & Joullié, M. M. Approaches to cyclophane-types of cyclopeptide alkaloids. *Chem. Rec.* **21**,
847 906–923 (2021).
- 848 10. Montalbán-López, M. *et al.* New developments in RiPP discovery, enzymology and engineering. *Nat.*
849 *Prod. Rep.* **38**, 130–239 (2021).
- 850 11. Chigumba, D. N. *et al.* Discovery and biosynthesis of cyclic plant peptides via autocatalytic cyclases.
851 *Nat. Chem. Biol.* **18**, 18–28 (2022).
- 852 12. Lima, S. T. *et al.* A widely distributed biosynthetic cassette is responsible for diverse plant side chain
853 cross-linked cyclopeptides. *Angew. Chem. Int. Ed Engl.* **62**, (2023).
- 854 13. Hattori, J., Boutilier, K. A., van Lookeren Campagne, M. M. & Miki, B. L. A conserved BURP domain
855 defines a novel group of plant proteins with unusual primary structures. *Mol. Gen. Genet.* **259**, 424–
856 428 (1998).
- 857 14. Mydy, L. S. *et al.* An intramolecular macrocyclase in plant ribosomal peptide biosynthesis. *Nat.*
858 *Chem. Biol.* (2024) doi:10.1038/s41589-024-01552-1.
- 859 15. Lima, S. T. *et al.* Peptide recognition sequence guides catalytic side chain cross-linking of plant
860 peptides by copper-dependent cyclases. *J. Am. Chem. Soc.* **147**, 20284–20293 (2025).
- 861 16. Kandy, S. K., Pasquale, M. A. & Chekan, J. R. Aromatic side-chain crosslinking in RiPP biosynthesis.
862 *Nat. Chem. Biol.* **21**, 168–181 (2025).
- 863 17. Kupke, T., Kempter, C., Gnau, V., Jung, G. & Götz, F. Mass spectroscopic analysis of a novel
864 enzymatic reaction. Oxidative decarboxylation of the lantibiotic precursor peptide EpiA catalyzed by
865 the flavoprotein EpiD. *J. Biol. Chem.* **269**, 5653–5659 (1994).
- 866 18. Wiebach, V. *et al.* The anti-staphylococcal lipolanthines are ribosomally synthesized lipopeptides.
867 *Nat. Chem. Biol.* **14**, 652–654 (2018).
- 868 19. Claesen, J. & Bibb, M. Genome mining and genetic analysis of cypemycin biosynthesis reveal an
869 unusual class of posttranslationally modified peptides. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 16297–
870 16302 (2010).
- 871 20. Franz, L., Kazmaier, U., Truman, A. W. & Koehnke, J. Bottromycins - biosynthesis, synthesis and
872 activity. *Nat. Prod. Rep.* **38**, 1659–1683 (2021).
- 873 21. Crone, W. J. K., Leeper, F. J. & Truman, A. W. Identification and characterisation of the gene cluster
874 for the anti-MRSA antibiotic bottromycin: expanding the biosynthetic diversity of ribosomal peptides.
875 *Chem. Sci.* **3**, 3516 (2012).
- 876 22. Minami, Y. *et al.* Structure of cypemycin, a new peptide antibiotic. *Tetrahedron Lett.* **35**, 8001–8004
877 (1994).
- 878 23. Adam, S. *et al.* Characterization of the stereoselective P450 enzyme BotCYP enables the in vitro
879 biosynthesis of the bottromycin core scaffold. *J. Am. Chem. Soc.* **142**, 20560–20565 (2020).

- 880 24. Bruender, N. A. & Bandarian, V. The radical S-adenosyl-L-methionine enzyme MftC catalyzes an
881 oxidative decarboxylation of the C-terminus of the MftA peptide. *Biochemistry* **55**, 2813–2816 (2016).
- 882 25. Khaliullin, B., Ayikpoe, R., Tuttle, M. & Latham, J. A. Mechanistic elucidation of the mycofactocin-
883 biosynthetic radical S-adenosylmethionine protein, MftC. *J. Biol. Chem.* **292**, 13022–13033 (2017).
- 884 26. Nguyen, D. T. *et al.* Biosynthesis of macrocyclic peptides with C-terminal β -amino- α -keto acid groups
885 by three different metalloenzymes. *ACS Cent. Sci.* **10**, 1022–1032 (2024).
- 886 27. Smith, T. E. *et al.* Accessing chemical diversity from the uncultivated symbionts of small marine
887 animals. *Nat. Chem. Biol.* **14**, 179–185 (2018).
- 888 28. Liang, H. *et al.* Genomic and metabolic analyses reveal antagonistic lanthipeptides in archaea.
889 *Microbiome* **11**, 74 (2023).
- 890 29. Ortiz-López, F. J. *et al.* Cacaoidin, first member of the new lanthidin RiPP family. *Angew. Chem.*
891 *Weinheim Bergstr. Ger.* **132**, 12754–12758 (2020).
- 892 30. Román-Hurtado, F., Sánchez-Hidalgo, M., Martín, J., Ortiz-López, F. J. & Genilloud, O. Biosynthesis
893 and heterologous expression of cacaoidin, the first member of the lanthidin family of RiPPs.
894 *Antibiotics (Basel)* **10**, 403 (2021).
- 895 31. Lacey, E., Edgar, J. A. & Culvenor, C. C. J. Interaction of phomopsin A and related compounds with
896 purified sheep brain tubulin. *Biochem. Pharmacol.* **36**, 2133–2138 (1987).
- 897 32. Ding, W. *et al.* Biosynthetic investigation of phomopsins reveals a widespread pathway for ribosomal
898 natural products in Ascomycetes. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 3521–3526 (2016).
- 899 33. Kalyon, B. *et al.* Plantazolicin A and B: structure elucidation of ribosomally synthesized
900 thiazole/oxazole peptides from *Bacillus amyloliquefaciens* FZB42. *Org. Lett.* **13**, 2996–2999 (2011).
- 901 34. Zhang, Q. & van der Donk, W. A. Catalytic promiscuity of a bacterial α -N-methyltransferase. *FEBS*
902 *Lett.* **586**, 3391–3397 (2012).
- 903 35. Boutilier, K. A. *et al.* Expression of the BnmNAP subfamily of napin genes coincides with the
904 induction of *Brassica* microspore embryogenesis. *Plant Mol. Biol.* **26**, 1711–1723 (1994).
- 905 36. Liu, M.-J. *et al.* The complex jujube genome provides insights into fruit tree biology. *Nat. Commun.* **5**,
906 5315 (2014).
- 907 37. Ghedira, K. *et al.* Two cyclopeptide alkaloids from *Zizyphus lotus*. *Phytochemistry* **32**, 1591–1594
908 (1993).
- 909 38. Han, B. H., Park, M. H. & Park, J. H. Chemical and pharmacological studies on sedative cyclopeptide
910 alkaloids in some Rhamnaceae plants. *Pure Appl. Chem.* **61**, 443–448 (1989).
- 911 39. Sainsbury, F., Thuenemann, E. C. & Lomonosoff, G. P. pEAQ: versatile expression vectors for easy
912 and quick transient expression of heterologous proteins in plants. *Plant Biotechnol. J.* **7**, 682–693
913 (2009).
- 914 40. Han, J. *et al.* Cyclopeptide alkaloids from *Zizyphus apetala*. *J. Nat. Prod.* **74**, 2571–2575 (2011).
- 915 41. Um, S. *et al.* Chromatographic determination of the absolute configuration in sanjoinine A that
916 increases nitric oxide production. *Biomol. Ther. (Seoul)* **31**, 566–572 (2023).
- 917 42. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool.
918 *J. Mol. Biol.* **215**, 403–410 (1990).
- 919 43. Abramson, J. *et al.* Accurate structure prediction of biomolecular interactions with AlphaFold 3.
920 *Nature* **630**, 493–500 (2024).
- 921 44. Koehntop, K. D., Emerson, J. P. & Que, L., Jr. The 2-His-1-carboxylate facial triad: a versatile
922 platform for dioxygen activation by mononuclear non-heme iron(II) enzymes. *J. Biol. Inorg. Chem.* **10**,
923 87–93 (2005).
- 924 45. Takehara, S. *et al.* A common allosteric mechanism regulates homeostatic inactivation of auxin and
925 gibberellin. *Nat. Commun.* **11**, 2143 (2020).
- 926 46. Ingold, Z., Grogan, G. & Lichman, B. R. Structure and mutation of deoxypodophyllotoxin synthase
927 (DPS) from *Podophyllum hexandrum*. *Front. Catal.* **3**, (2023).
- 928 47. Wenger, E. S. *et al.* Optimized substrate positioning enables switches in the C-H cleavage site and

- 929 reaction outcome in the hydroxylation-epoxidation sequence catalyzed by hyoscyamine 6 β -
930 hydroxylase. *J. Am. Chem. Soc.* **146**, 24271–24287 (2024).
- 931 48. Jockmann, E. *et al.* How to tell an N from an O: Controlling the chemoselectivity of
932 methyltransferases. *ACS Catal.* **15**, 6410–6425 (2025).
- 933 49. Xiao, D., East, S. P. & Joullié, M. M. Total synthesis of sanjoinine A (franguloline). *Tetrahedron Lett.*
934 **39**, 9631–9632 (1998).
- 935 50. Srinivasan, P. & Smolke, C. D. Biosynthesis of medicinal tropane alkaloids in yeast. *Nature* **585**,
936 614–619 (2020).
- 937 51. Kersten, R. D. *et al.* Gene-Guided Discovery and Ribosomal Biosynthesis of Moroidin Peptides. *J.*
938 *Am. Chem. Soc.* **144**, 7686–7692 (2022).
- 939 52. Wang, X. *et al.* Large-scale transcriptome mining enables macrocyclic diversification and improved
940 bioactivity of the stephanotic acid scaffold. *Nat. Commun.* **16**, 4198 (2025).
- 941 53. Kersten, R. D. & Weng, J.-K. Gene-guided discovery and engineering of branched cyclic peptides in
942 plants. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E10961–E10969 (2018).
- 943 54. Nguyen, G. K. T. *et al.* Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and
944 synthesis. *Nat. Chem. Biol.* **10**, 732–738 (2014).
- 945 55. Harris, K. S. *et al.* Efficient backbone cyclization of linear peptides by a recombinant asparaginyl
946 endopeptidase. *Nat. Commun.* **6**, 10199 (2015).
- 947 56. Chekan, J. R., Estrada, P., Covello, P. S. & Nair, S. K. Characterization of the macrocyclase involved
948 in the biosynthesis of RiPP cyclic peptides in plants. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 6551–6556
949 (2017).
- 950 57. Rehm, F. B. H. *et al.* Papain-like cysteine proteases prepare plant cyclic peptide precursors for
951 cyclization. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 7831–7836 (2019).
- 952 58. Kim, C. Y. *et al.* The chloroalkaloid (-)-acutumine is biosynthesized via a Fe(II)- and 2-oxoglutarate-
953 dependent halogenase in Menispermaceae plants. *Nat. Commun.* **11**, 1867 (2020).
- 954 59. Zhao, L.-P. *et al.* Nonheme Fe 1,3-nitrogen migratases for asymmetric noncanonical amino acid
955 synthesis. *Nat. Chem. Biol.* (2025) doi:10.1038/s41589-025-01953-w.
- 956 60. Zhao, S., Wu, L., Xu, Y. & Nie, Y. Fe(II) and 2-oxoglutarate-dependent dioxygenases for natural
957 product synthesis: molecular insights into reaction diversity. *Nat. Prod. Rep.* **42**, 67–92 (2025).
- 958 61. Yu, C.-P. *et al.* Elucidating the reaction pathway of decarboxylation-assisted olefination catalyzed by
959 a mononuclear non-heme iron enzyme. *J. Am. Chem. Soc.* **140**, 15190–15193 (2018).
- 960 62. Crawford, J. M., Portmann, C., Zhang, X., Roeffaers, M. B. J. & Clardy, J. Small molecule perimeter
961 defense in entomopathogenic bacteria. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 10821–10826 (2012).
- 962 63. Copeland, R. A. *et al.* An iron(IV)-oxo intermediate initiating l-arginine oxidation but not ethylene
963 production by the 2-oxoglutarate-dependent oxygenase, ethylene-forming enzyme. *J. Am. Chem.*
964 *Soc.* **143**, 2293–2303 (2021).
- 965 64. Krebs, C., Galonić Fujimori, D., Walsh, C. T. & Bollinger, J. M., Jr. Non-heme Fe(IV)-oxo
966 intermediates. *Acc. Chem. Res.* **40**, 484–492 (2007).
- 967 65. Hausinger, R. P. Biochemical Diversity of 2-Oxoglutarate-Dependent Oxygenases. In 2-Oxoglutarate-
968 Dependent Oxygenases. *The Royal Society of Chemistry: Cambridge* 1–58 (2015).
- 969 66. Purpero, V. & Moran, G. R. The diverse and pervasive chemistries of the alpha-keto acid dependent
970 enzymes. *J. Biol. Inorg. Chem.* **12**, 587–601 (2007).
- 971 67. Zhang, Z. *et al.* Jujube metabolome selection determined the edible properties acquired during
972 domestication. *Plant J.* **109**, 1116–1133 (2022).
- 973 68. Zwick, C. R. & Renata, H. Harnessing the biocatalytic potential of iron- and α -ketoglutarate-
974 dependent dioxygenases in natural product total synthesis. *Nat. Prod. Rep.* **37**, 1065–1079 (2020).
- 975 69. Papadopoulou, A., Meyer, F. & Buller, R. M. Engineering Fe(II)/ α -ketoglutarate-dependent
976 halogenases and desaturases. *Biochemistry* **62**, 229–240 (2023).
- 977 70. Paton, A. *et al.* Generation of connections between protein sequence space and chemical space to

- 978 enable a predictive model for biocatalysis. *ChemRxiv* (2024) doi:10.26434/chemrxiv-2024-w4dtr.
- 979 71. Leinonen, R., Sugawara, H., Shumway, M. & International Nucleotide Sequence Database
980 Collaboration. The sequence read archive. *Nucleic Acids Res.* **39**, D19-21 (2011).
- 981 72. Wang, M. *et al.* Sharing and community curation of mass spectrometry data with Global Natural
982 Products Social Molecular Networking. *Nat. Biotechnol.* **34**, 828–837 (2016).
- 983 73. Bankevich, A. *et al.* SPAdes: a new genome assembly algorithm and its applications to single-cell
984 sequencing. *J. Comput. Biol.* **19**, 455–477 (2012).
- 985 74. Bushmanova, E., Antipov, D., Lapidus, A. & Prjibelski, A. D. rnaSPAdes: a de novo transcriptome
986 assembler and its application to RNA-Seq data. *Gigascience* **8**, (2019).
- 987 75. Priyam, A. *et al.* Sequenceserver: A Modern Graphical User Interface for Custom BLAST Databases.
988 *Mol. Biol. Evol.* **36**, 2922–2924 (2019).
- 989 76. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification.
990 *Nat. Biotechnol.* **34**, 525–527 (2016).
- 991 77. Shen, W., Sipos, B. & Zhao, L. SeqKit2: A Swiss army knife for sequence and alignment processing.
992 *Imeta* **3**, e191 (2024).
- 993 78. Hart, A. J. *et al.* EnTAP: Bringing faster and smarter functional annotation to non-model eukaryotic
994 transcriptomes. *Mol. Ecol. Resour.* **20**, 591–604 (2020).
- 995 79. UniProt Consortium. UniProt: The universal protein knowledgebase in 2025. *Nucleic Acids Res.* **53**,
996 D609–D617 (2025).
- 997 80. Ousley, D. A., Wang, X., Mydy, L. S. & Kersten, R. D. Plant genome mining of burpitides from fused
998 precursor peptides. in *Methods in Enzymology* (Elsevier, 2025).
- 999 81. Fujii, K., Ikai, Y., Oka, H., Suzuki, M. & Harada, K.-I. A nonempirical method using LC/MS for
1000 determination of the absolute configuration of constituent amino acids in a peptide: Combination of
1001 marfey's method with mass spectrometry and its practical application. *Anal. Chem.* **69**, 5146–5151
1002 (1997).
- 1003 82. Vijayasarathy, S. *et al.* C3 and 2D C3 Marfey's methods for amino acid analysis in natural products.
1004 *J. Nat. Prod.* **79**, 421–427 (2016).
- 1005 83. Gasteiger, E. *et al.* Protein identification and analysis tools on the ExPASy server. in *The Proteomics*
1006 *Protocols Handbook* 571–607 (Humana Press, Totowa, NJ, 2005).
- 1007 84. Damiani, T. *et al.* A universal language for finding mass spectrometry data patterns. *Nat. Methods*
1008 **22**, 1247–1254 (2025).
- 1009 85. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular
1010 interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
- 1011 86. Burkhart, B. J., Hudson, G. A., Dunbar, K. L. & Mitchell, D. A. A prevalent peptide-binding domain
1012 guides ribosomal natural product biosynthesis. *Nat. Chem. Biol.* **11**, 564–570 (2015).
- 1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026






Figure 1 | C-terminal RiPP decarboxylation. (A) Plant cyclopeptide alkaloid structures. Adouetine X and jubanine H are representatives of decarboxylated (classical) CPAs with a C-terminal hydroxystyrylamine. Selanine B and arabipeptin A represent characterized CPA-burpitide RiPPs with a C-terminal tyrosine. (B) Oxidative decarboxylation in bottomycin A2 biosynthesis via CYP450 enzyme BotCYP. (C) C-terminal oxidative decarboxylation of epidermin precursor peptide via flavoenzyme EpiD and subsequent aminovinyl-cysteine formation. (D) Oxidative decarboxylation of a C-terminal tyrosine during mycofactocin biosynthesis catalyzed by radical SAM enzyme MftC. (E) Oxidative decarboxylation by MNIO enzyme ApyH with RRE-containing protein ApyI towards C-terminal β -amino- α -keto acid formation. Decarboxylation modifications are highlighted in red in B-D. Abbreviations: FMN - flavin mononucleotide, SAM - S-adenosylmethionine, MNIO - multinuclear non-heme-iron oxidative enzyme, RRE - RiPP recognition element⁸⁶.

1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049




1050
 1051 **Figure 2 | Characterization of 14-membered CPA-burpitide cyclase ZjuBURP from *Ziziphus jujuba*.**
 1052 (A) *Ziziphus jujuba* cultivar Dongzao. (B) *ZjuBURP* locus in the *Z. jujuba* genome with co-localized *ZjuPrec-*
 1053 *FPIY* gene. Predicted core peptides are highlighted in blue and red color. (C) LCMS detection of cyFPIY
 1054 peptide in transgenic *N. benthamiana* after 7 days of coexpression of *ZjuPrec-5xFPIY* and *ZjuBURP* or a
 1055 *ZjuPrec-5xFPIY-ZjuBURP-fusion* construct. (D) cyFPIY structure isolated from transgenic *N. benthamiana*
 1056 after scaled expression of *ZjuPrec-5xFPIY-ZjuBURP-fusion*. Abbreviations: ncRNA - non-coding RNA, EIC
 1057 - extracted ion chromatogram.

1058
 1059
 1060
 1061
 1062
 1063
 1064
 1065
 1066
 1067
 1068
 1069
 1070
 1071
 1072
 1073
 1074
 1075
 1076
 1077
 1078
 1079
 1080
 1081
 1082
 1083
 1084
 1085
 1086
 1087




1088
1089 **Figure 3 | Discovery and characterization of a non-heme-iron and 2-oxoglutarate-dependent enzyme**
1090 **for oxidative CPA decarboxylation.** (A) EIC traces of cyFPIY and decarboxylated cyFPIY in methanolic
1091 extracts of transgenic *N. benthamiana* leaves expressing ZjuPrec-3xFPIY-ZjuBURP with or without
1092 candidate decarboxylase ZjuDC for 7 days. (B) *In vitro* reconstitution of ZjuDC activity in the presence of
1093 Fe(II) and 2OG. (C) *In vitro* cofactor and substrate screening assays of ZjuDC. (D) ZjuDC reaction. (E)
1094 Characterization of oxidative decarboxylation in cyFPIY by ZjuDC reaction. (F) Kinetic characterization of
1095 ZjuDC with cyFPIY substrate. Abbreviations: 2OG - 2-oxoglutarate, EIC – extracted ion chromatogram.

1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106



1107
1108 **Figure 4 | Discovery and characterization of a SAM-dependent *N*-methyltransferase in CPA**
1109 **biosynthesis from jujube. (A)** EIC traces of decarboxylated cy $FPIY$ and *N,N*-dimethylated cy $FPIY$ -dc
1110 (lotusine A) in methanolic extracts of transgenic *N. benthamiana* leaves expressing ZjuPrec-3x $FPIY$ -
1111 ZjuBURP and ZjuDC with or without candidate *N*-methyltransferase ZjuNMT for 7 days. **(B)** *In vitro*
1112 reconstitution of ZjuNMT activity in the presence of SAM. **(C)** Lotusine A structure with detected *N*-methyl
1113 NMR correlations. **(D)** Substrate promiscuity assay of ZjuNMT with cy $FPIY$ as a substrate including SAM-
1114 dependence assay. **(E)** *N,N*-Me₂-cy $FPIY$ structure predicted by tandem mass spectrometry (**Figure S36**).
1115 Abbreviations: SAM - S-adenosylmethionine.

1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139



1140
 1141 **Figure 5 | Biosynthesis of medicinal CPAs via ZjuDC and ZjuNMT.** (A) Biosynthetic route to sanjoinine
 1142 A. (B) Biosynthetic route to adouetine X. (C) In planta and in vitro biosynthesis of sanjoinine A and adouetine
 1143 X from SkrBURP-5xFLLY or SkrBURP-5xLLIY products, respectively. (D) *In planta* diversification of
 1144 sanjoinine A and adouetine X at position 3 via SkrBURP, ZjuDC and ZjuNMT in *Nicotiana benthamiana*.
 1145 Green color indicates detected analytes, white color indicates no detected analytes.